

## TOTAL PRODUCTION

Nom de l'équipe pour le contrat en cours: Cell Death and Drug Resisance in Lymphoproliferative Disorders

Nom du directeur pour le contrat en cours: Santos A. SUSIN

Nom de l'équipe pour le contrat à venir : Cell Death and Drug Resisance in Hematological Disorders

Nom du directeur pour le contrat à venir : Santos A. SUSIN / Florence NGUYEN-KHAC

### I. PRODUITS DE LA RECHERCHE

*Publications done in collaboration with another team of the CRC are flagged with ■*

#### 1. Journaux / revues

##### Articles scientifiques

##### Bibliometric analysis

Since January 2012, our team has participated in **170 publications**, thereby underlining the international recognition and relevance of the work developed by the team. Of these, **124** are original articles and **46** reviews. Among the original articles, **30 %** are in journals with **IF >10** (including Lancet, Cancer Discovery, PLoS Medicine, J Clin Oncol, Leukemia, J Exp Med, or Blood) and **45 %** are **IF from 5 to 10** (including Cell Death and Differentiation, Oncotarget, Clin Cancer Res, or Haematologica). **4** Editorial comments, **12** technical papers, **1** book, **7** book chapters, and **4** patents with international extension complete our scientific production.

##### Original articles

#### 2017

1. Cosson A, Chapiro E, Bougacha N, Lambert J, Herbi L, Cung HA, Algrin C, Keren B, Damm F, Gabillaud C, Brunelle-Navas MN, Davi F, Merle-Béral H, Le Garff-Tavernier M, Roos-Weil D, Choquet S, Uzunov M, Morel V, Leblond V, Maloum K, Lepretre S, Feugier P, Lesty C, Lejeune J, Sutton L, Landesman Y, Susin SA\*, Nguyen-Khac F\*. Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1. *Leukemia*. 2017 Apr. doi: 10.1038/leu.2017.100. [Epub ahead of print]. \* Senior co-authors. (IF: 11.7)
2. Cabon L, Bertaux A, Brunelle-Navas, M-N, Namazany I, Scourzic L, Delavallee L, Vela L, Baritaud M, Bouchet S, Lopez C, Quang Van V, Garbin K, Château D, Gilard F, Sarfati M, Mercher T, Bernard OA, and Susin SA. AIF loss deregulates hematopoiesis and reveals a different metabolic reprogramming in bone marrow cells and thymocytes. *Cell Death Differ*. in press. (IF: 8.34)
3. Durham BH, Roos-Weil D (first co-author), Baillou C, Cohen-Aubart F, Yoshimi A, Miyara M, Papo M, ..., Bernard OA, Amoura Z, Abdel-Wahab O, Lemoine FM, Haroche J, Emile JF. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. *Blood*. 2017 May 31. pii: blood-2016-12-757377. doi:10.1182/blood-2016-12-757377. [Epub ahead of print] PubMed PMID: 28566492. (IF: 13.16)
4. Costopoulos M, Kim R, Choquet S, Maloum K, Houillier C, Algrin C, Settegrana C, Villemonteix J, Brissard M, Quiney C, Bernard S, Davi F., Thieblemont C., Hoang-Xuan K., Leblond V., Merle-Beral H, Le Garff-Tavernier M. Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. Accepted in *Seminars in Hematology* (IF:4.43)

5. Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan Djurasevic T, Catherwood MA, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann CU, Dohner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K. Chronic lymphocytic leukemia with mutated *ighv4-34* receptors: shared and distinct immunogenetic features and clinical outcomes. *Clin Cancer Res*. 2017 May 23. doi:10.1158/1078-0432.CCR-16-3100. [Epub ahead of print]. (IF: 9.6)
6. Fleury C, Passet M, Settegrana C, Simon L, Chapiro E, Trinquand A, Safra Zaghouani I, Uzunov M, Le Garff-Tavernier M, Armand M, Costopoulos M. An unusual case of acute leukemia. *Ann Biol Clin (Paris)*. 2017;75(3):339-347. (IF: 0.22)
7. Langerak AW, Brüggemann M, Davi F, Darzentas N, van Dongen JJM, Gonzalez D, Cazzaniga G, Giudicelli V, Lefranc MP, Giraud M, Macintyre EA, Hummel M, Pott C, Groenen PJTA, Stamatopoulos K; EuroClonality-NGS Consortium. High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges. *J Immunol*. 2017 May;198(10):3765-3774. (IF: 4.85)
8. Ustun C, Williams S, Skendzel S, Kodali B, Arock M, Gotlib J, Vallera DA, Cooley S, Felices M, Weisdorf D, Miller J. Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia. *American J Hematol*. 2017 May; 92(5): E66-E8. (IF: 5.27)
9. ■ Fadel F, André-Grégoire G, Bauvois B, Bouchet S, Sierra-Ramos C, Polito A, Mansart A, Alvarez de la Rosa D, Annane D, Jaisser F. Aldosterone and Vascular Mineralocorticoid Receptors in Murine Endotoxin and Human Septic Shock. *Crit Care Med*, Published: 2017 Apr (Epub 2017 Apr 25). (IF: 7.05)
10. Giorni C, Costopoulos M, Bachelot-Loza C, Pouard P, Raïsky O, Borgel D, Lasne D. Platelet-mapping assay for monitoring antiplatelet therapy during mechanical circulatory support in children: a retrospective observational study, accepted in *Research and Practice in Thrombosis and Haemostasis* (April 2017) (IF: 5.62)
11. Houillier C, Ghesquières H, Chabrot C, Soussain C, Ahle G, Choquet S, Nicolas-Virelizier E, Bay JO, Vargaftig J, Gaultier C, Touitou V, Martin-Duverneuil N, Cassoux N, Le Garff-Tavernier M, Costopoulos M, Faurie P, Hoang-Xuan K. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. *J Neurooncol*. 2017 Apr. doi: 10.1007/s11060-017-2435-7. (IF: 2.98)
12. Algrin C, Golmard JL, Michallet M, Reman O, Huynh A, Perrot A, Sirvent A, Plesa A, Salaun V, Béné MC, Bories D, Tournilhac O, Merle-Béral H, Leblond V, Le Garff-Tavernier M, Dhedin N. Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia. *Eur J Haematol*. 2017 Apr; 98(4):363-370. (IF: 2.65)
13. Ducassou S, Prouzet-Mauleon V, Deau MC, Brunet de la Grange P, Cardinaud B, Soueidan H, Quelen C, Brousset P, Pasquet JM, Moreau-Gaudry F, Arock M, Mahon FX, Lippert E. MYB-GATA1 fusion promotes basophilic leukaemia: involvement of IL33 and nerve growth factor receptors. *J Pathol*. 2017 April. doi: 10.1002/path.4908. [Epub ahead of print] (IF: 6.89)
14. Comarmond C, Garrido M, Pol S, Desbois AC, Costopoulos M, Le Garff-Tavernier M, Si Ahmed SN, Atric L, Fontaine H, Bellier B, Maciejewski A, Rosenzwajg M, Klatzmann D, Musset L, Poynard T, Cacoub P, Saadoun D. Direct-acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-induced Cryoglobulinemia Vasculitis. *Gastroenterology*. 2017 Mar. pii: S0016-5085(17)30235-4. (IF: 18.39)
15. Lyberg K, Ali HA, Grootens J, Kjellander M, Tirfing M, Arock M, Hagglund H, Nilsson G, Ungerstedt J. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis. *Oncotarget*. 2017 February; 8(6): 9647-59. (IF: 5.16)
16. Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton LA, Blakemore SJ, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dürken B, Schmitt CA, Smedby KE, Juliusson G, Giacomelli B, Blachly JS, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak AW, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard OA, Nguyen-Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes CC, Strefford JC, Rosenquist R, Damm F. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. *Leukemia*. 2017 Jan. doi: 10.1038/leu.2016.359. [Epub ahead of print]. (IF: 11.7)
17. Vignon M, Javaugue V, Alexander MP, El-Karoui K, Karras A, Roos-Weil D, ..., Arnulf B, Bridoux F, Leung N, Feraud JP. Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. *Leukemia*. 2017 Jan;31(1):123-129. (IF: 11.7)

## 2016

18. Bchir S, Nasr HB, Bouchet S, Benzarti M, Garrouch A, Tabka Z, Susin SA, Chahed K, Bauvois B. Concomitant elevations of MMP-9, NGAL, proMMP-9/NGAL and neutrophil elastase in serum of smokers with chronic obstructive pulmonary disease. *J Cell Mol Med*, Published: 2016-Dec (Epub 2016 Dec 22) (IF: 4.49)

19. Mansouri L, Noerenberg D, Young E, Mylonas E, ..., Roos-Weil D, Schmitt CA, Munch-Petersen HD, Zenz T, Hansmann ML, Strefford JC, Enblad G, Bernard OA, Ralfkiaer E, ..., Rosenquist R, Damm F. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. *Blood*. 2016 Dec;128(23):2666-2670. (IF: 13.16)
20. Authier F, Djavaheri-Mergny M, Séverine Lorin S, Frénoy JP, Desbuquois B. Fate and action of ricin in rat liver in vivo: translocation of endocytosed ricin into cytosol and induction of intrinsic apoptosis by ricin B-chain. *Cellular Microbiology*. 2016 Dec; 18(12):1800-1814. (IF: 4.554)
21. Bibi S, Zhang Y, Hugonin C, Mangean MD, He L, Wedeh G, Launay JM, Van Rijn S, Wurdinger T, Louache F, Arock M. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase. *Oncotarget*. 2016 Dec; 7(50): 82985-3000. (IF: 5.16)
22. Alric L, Besson C, Lapidus N, Jeannel J, Michot JM, Cacoub P, Canioni D, Pol S, Davi F, Rabiega P, Ysebaert L, Bonnet D, Hermine O. Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-CStudy. *PLoS One*. 2016 Oct;11(10):e0162965. (IF: 2.80)
23. Saadoun D, Thibault V, Si Ahmed SN, Alric L, Mallet M, Guillaud C, Izzedine H, Plaisier A, Fontaine H, Costopoulos M, Le Garff-Tavernier M, Hezode C, Pol S, Musset L, Poynard T, Cacoub P. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. *Ann Rheum Dis*. 2016 Oct;75(10):1777-82. (IF: 12.81)
24. Bystry V, Reigl T, Krejci A, Demko M, Hanakova B, Gioni A, Knecht H, Schlitt M, Dreger P, Sellner L, Herrmann D, Pingeon M, Boudjoghra M, Rijntjes J, Pott C, Langerak AW, Groenen PJ, Davi F, Brüggemann M, Darzentas N; also on Behalf of EuroClonality-NGS. ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data. *Bioinformatics*. 2016 Oct. pii: btw634. (IF: 7.30)
25. Bigenwald C, Harel S, Chevignon F, Roos-Weil D, Bernard OA, Amorim S, Brice P, Adès L, Nloga AM, Sébert M, Braun T, Eclache V, Thieblemont C, Fenaux P. Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related? *Br J Haematol*. 2016 Sep 23. doi:10.1111/bjh.14323. (IF: 5.67)
26. Denèfle T, Boullet H, Herbi L, Newton C, Martinez-Torres AC, Guez A, Pramil E, Quiney C, Pourcelot M, Levasseur MD, Lardé E, Moumné R, Ogi FX, Grondin P, Merle-Beral H, Lequin O, Susin SA\*, Karoyan P\*. *Thrombospondin-1 Mimetic Agonist Peptides Induce Selective Death in Tumor Cells: Design, Synthesis, and Structure-Activity Relationship Studies*. *J Med Chem.*, vol. 59, pp. 8412-21. \* Senior co-authors. (IF: 6.2)
27. Navrkalova V, Young E, Baliakas P, Radova L, Sutton LA, Plevova K, Mansouri L, Ljungström V, Ntoufa S, Davis Z, Juliusson G, Smedby KE, Belessi C, Panagiotidis P, Touloumenidou T, Davi F, Langerak AW, Ghia P, Strefford JC, Oscier D, Mayer J, Stamatopoulos K, Pospisilova S, Rosenquist R, Trbusek M. ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres. *Haematologica*. 2016 Sep;101(9):e369-73. (IF: 7.70)
28. Nguyen DT, Houllier C, Choquet S, Cassoux N, Soussain C, Le Cossec C, Le Garff-Tavernier M, Costopoulos M, LeHoang P, Bodaghi B, Omuro A, Hoang-Xuan K, Touitou V. Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control. *Ophthalmology*. 2016 Sep;123(9):2047-50. (IF: 8.20)
29. Sutton LA, Young E, Baliakas P, Hadzidimitriou A, Moysiadis T, Plevova K, Rossi D, Kminkova J, Stalika E, Pedersen LB, Malcikova J, Agathangelidis A, Davis Z, Mansouri L, Scarfo L, Boudjoghra M, Navarro A, Muggen AF, Yan XJ, Nguyen-Khac F, Larrayoz M, Panagiotidis P, Chiorazzi N, Niemann CU, Belessi C, Campo E, Strefford JC, Langerak AW, Oscier D, Gaidano G, Pospisilova S, Davi F, Ghia P, Stamatopoulos K, Rosenquist R; ERIC, the European Research Initiative on CLL. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. *Haematologica*. 2016 Aug;101(8):959-67. (IF: 7.70)
30. Nguyen-Them L, Costopoulos M, Tanguy ML, Houllier C, Choquet S, Benanni H, Elias-Shamieh R, Armand M, Faivre G, Glaisner S, Malak S, Vargaftig J, Hoang-Xuan K, Ahle G, Touitou V, Cassoux N, Davi F, Merle-Béral H, Le Garff-Tavernier M, Soussain C; French LOC Network for CNS Lymphoma. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. *Eur J Cancer*. 2016 Jul;61:69-76. (IF: 6.02)
31. Costopoulos M, Touitou V, Golmard JL, Darugar A, Fisson S, Bonnemye P, Le Lez ML, Soussain C, Cassoux N, Lamy T, Le Hoang P, Bodaghi B, Merle-Béral H, Le Garff-Tavernier M. ISOLD: A New Highly Sensitive Interleukin Score for Intraocular Lymphoma Diagnosis. *Ophthalmology*. 2016 Jul;123(7):1626-8. (IF: 8.20)
32. Baliakas P, Puiggros A, Xochelli A, Sutton LA, Nguyen-Khac F, Gardiner A, Plevova K, Minga E, Hadzidimitriou A, Walewska R, McCarthy H, Ortega M, Collado R, Gonzalez T, Granada I, Luno E, Kotaskova J, Moysiadis T, Davis Z, Stavroyianni N, Anagnostopoulos A, Strefford JC, Pospisilova S, Davi F, Athanasiadou A, Rosenquist R, Oscier D, Espinet B, Stamatopoulos K. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. *Haematologica* 2016 Jul;101:e299-302. (IF: 7.70)
33. Rouet A, Aouba A, Damaj G, Soucie E, Hanssens K, Chandesris MO, Livideanu CB, Dutertre M, Durieu I, Grandpeix-Guyodo C, Barete S, Bachmeyer C, Soria A, Frenzel L, Fain O, Grosbois B, de Gennes C, Hamidou M, Arlet JB, Launay D, Lavigne C, Arock M, Lortholary O, Dubreuil P, Hermine O, Georgin-Lavialle S. Mastocytosis among elderly patients: A multicenter retrospective French study on 53 patients. *Medicine*. 2016 June; 95(24): e3901. (IF 1.80)

34. Canioni D, Michot JM, Rabiega P, Molina TJ, Charlotte F, Lazure T, Davi F, Settegrana C, Berger F, Alric L, Cacoub P, Terrier B, Suarez F, Sibon D, Dupuis J, Feray C, Tilly H, Pol S, Deau Fischer B, Roulland S, Thieblemont C, Leblond V, Carrat F, Hermine O, Besson C; national ANRS HC13 LymphoC study. In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. *PLoS One*. 2016 Jun;11(6):e0156384. (IF: 2.80)
35. Emadali A, Houghoughi N, Duley S, Hajmirza A, Verhoeyen E, Cosset FL, Bertrand P, Roumier C, Roggy A, Suchaud-Martin C, Chauvet M, Bertrand S, Hamaidia S, Rousseaux S, Josserand V, Charles J, Templier I, Maeda T, Bruder-Costa J, Chaperot L, Plumas J, Jacob MC, Bonnefoix T, Park S, Gressin R, Tensen CP, Mecucci C, Macintyre E, Leroux D, Brambilla E, Nguyen-Khac F, Luquet I, Penther D, Bastard C, Jardin F, Lefebvre C, Garnache F, Callanan MB. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. *Blood* 2016 Jun;127:3040-3053. (IF: 13.16)
36. Bachy E, Urb M, Chandra S, Robinot R, Bricard G, de Bernard S, Traverse-Glehen A, Gazzo S, Blond O, Khurana A, Baseggio L, Heavican T, Ffrench M, Crispatzu G, Mondière P, Schrader A, Taillardet M, Thauinat O, Martin N, Dalle S, Le Garff-Tavernier M, Salles G, Lachuer J, Hermine O, Asnafi V, Roussel M, Lamy T, Herling M, Iqbal J, Buffat L, Marche PN, Gaulard P, Kronenberg M, Defrance T, Genestier L. CD1d-restricted peripheral T cell lymphoma in mice and humans. *J Exp Med*. 2016 May;213(5):841-57. (IF: 11.99)
37. Berquet L, Valleron W, Grgurevic S, Quelen C, Zaki O, Quillet-Mary A, Davi F, Brousset P, Bousquet M, Ysebaert L. Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia. *Br J Haematol*. 2016 Mar;172(5):819-23. (IF: 5.67)
38. Ljungström V, Cortese D, Young E, Pandzic T, Mansouri L, Plevova K, Ntoufa S, Baliakas P, Clifford R, Sutton LA, Blakemore SJ, Stavroyianni N, Agathangelidis A, Rossi D, Höglund M, Kotaskova J, Juliusson G, Belessi C, Chiorazzi N, Panagiotidis P, Langerak AW, Smedby KE, Oscier D, Gaidano G, Schuh A, Davi F, Pott C, Strefford JC, Trentin L, Pospisilova S, Ghia P, Stamatopoulos K, Sjöblom T, Rosenquist R. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. *Blood*. 2016 Feb;127(8):1007-16. (IF: 11.84)
39. Bouchet S, Tang R, Fava F, Legrand O, Bauvois B. The CNGRC-GG-D(KLAKLAK)2 peptide induces a caspase-independent, Ca<sup>2+</sup>-dependent death in human leukemic myeloid cells by targeting surface aminopeptidase N/CD13. *Oncotarget*. 2016 April; 7(15):19445-67. (IF: 5.16)
40. Berquet L, Valleron W, Grgurevic S, Quelen C, Zaki O, Quillet-Mary A, Davi F, Brousset P, Bousquet M, Ysebaert L. Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia. *Br J Haematol*. 2016 Mar;172(5):819-23. (IF: 5.67)
41. Guièze R, Damaj G, Pereira B, Robin M, Chevallier P, Michallet M, Vigouroux S, Beguin Y, Blaise D, El Cheikh J, Roos-Weil D, ..., Guillerme G, Yakoub-Agha I. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies. *Biol Blood Marrow Transplant*. 2016 Feb;22(2):240-7. (IF: 3.98)
42. Rabenhorst A, Leja S, Schwaab J, Gehring M, Forster A, Arock M, Reiter A, Raap U, Hartmann K. Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity. *J Allergy Clin Immunol*. 2016 Jan; 137(1): 314-8. (IF: 12.485)
43. Bouchet S, Marion Piedfer M, Susin SA, Dauzonne D, Bauvois B. In vitro activity of some flavonoid derivatives on human leukemic myeloid cells: evidence for aminopeptidase-N (CD13) inhibition, antiproliferative and cell death properties. *AIMS Molecular Science* 2016 Jan; 3(3) : 368-385.
44. Liu Y, Aron-Wisniewsky J, Marcelin G, Genser L, Le Naour G, Torcivia A, Bauvois B, Bouchet S, Pelloux V, Sasso M, Miette V, Tordjman J, Clément K. Accumulation and Changes in Composition of Collagens in Subcutaneous Adipose Tissue After Bariatric Surgery. *J Clin Endocrinol Metab*. 2016 Jan;101(1):293-304. (IF: 5.455)

## 2015

45. Bchir S, Nasr HB, Hakim IR, Anes AB, Yacoub S, Garrouch A, Benzarti M, Bauvois B, Tabka Z, Chahed K. Matrix Metalloproteinase-9 (279R/Q) Polymorphism is Associated with Clinical Severity and Airflow Limitation in Tunisian Patients with Chronic Obstructive Pulmonary Disease. *Mol Diagn Ther*. 2015 Dec;19(6):375-87. (IF: 1.90)
46. Debliquis A, Wagner-Ballon O, Le Garff-Tavernier M, Fossat C, Chatelain B, Letestu R, Drénou B; HPN-AFC Group. Evaluation of paroxysmal nocturnal hemoglobinuria screening by flow cytometry through multicentric interlaboratory comparison in four countries. *Am J Clin Pathol*. 2015 Dec;144(6):858-68. (IF: 2.40)
47. Langenfeld F, Guarracino Y, Arock M, Trouve A, Tchertanov L. How Intrinsic Molecular Dynamics Control Intramolecular Communication in Signal Transducers and Activators of Transcription Factor STAT5. *PLoS One*. 2015 Dec; 10(12): e0145142. (IF: 2.80)
48. Wedeh G, Cerny-Reiterer S, Eisenwort G, Herrmann H, Blatt K, Hadzijusufovic E, Sadovnik I, Mullauer L, Schwaab J, Hoffmann T, Bradner JE, Radia D, Sperr WR, Hoermann G, Reiter A, Horny HP, Zuber J, Arock M, Valent P. Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. *Leukemia*. 2015 Nov; 29(11): 2230-7. (IF: 11.70)

49. Lazareth A, Song XY, Coquin A, Harel S, Karlin L, Belhadj K, Roos-Weil D, ..., Bories JC, Arnulf B. MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis. *Haematologica*. 2015 Nov;100(11):e471-4. (IF: 7.70)
50. Guiézen R, Robbe P, Clifford R, de Guibert S, Pereira S, Timbs A, Dilhuydy MS, Cabes M, Ysebaert L, Burns A, Nguyen-Khac F, Davi F, Véronèse L, Combes P, Le Garff-Tavernier M, Leblond V, Merle-Béral H, Alsolami R, Hamblin A, Mason J, Pettitt A, Hillmen P, Taylor J, Knight SJ, Tournilhac O, Schuh A. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. *Blood*. 2015 Oct;126(18):2110-7. (IF: 13.16)
51. Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Lepretre S, Dilhuydy MS, Bene MC, Nguyen-Khac F, Letestu R, Cymbalista F, De Guibert S, Aurrant T, Laribi K, Vilque JP, Tournilhac O, Delmer A, Feugier P, Cazin B, Michallet AS, Levy V, Troussard X, Delepine R, Tavernier E, Colombat P, Leblond V. Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia. *Leukemia & Lymphoma* 2015 Sep;1-7. (IF: 2.75)
52. Bouley J, Saad L, Grall R, Schellenbauer A, Biard D, Paget V, Morel-Altmeier S, Guipaud O, Chambon C, Salles B, Maloum K, Merle-Béral H, Chevillard S, Delic J. A new phosphorylated form of Ku70 identified in resistant leukemic cells confers fast but unfaithful DNA repair in cancer cell lines. *Oncotarget*. 2015 Sep;6(29):27980-8000. (IF 5.16)
53. Beaussant Y, Daguindau E, Pugin A, Mohty M, Avet-Loiseau H, Roos-Weil D, ..., Lioure B, Bulabois CE, Deconinck E; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). *Biol Blood Marrow Transplant*. 2015 Aug;21(8):1452-9. (IF: 4.70)
54. Villanueva R, Ferreira P, Marcuello C, Usón A, Miramar MD, Peleato ML, Lostao A, Susin SA, Medina M. Key Residues Regulating the Reductase Activity of the Human Mitochondrial Apoptosis Inducing Factor. *Biochemistry*. 2015 Aug 25;54(33):5175-84. (IF 2.938)
55. Mansouri L, Sutton LA, Ljungström V, Bondza S, Arngarden L, Bhoi S, Larsson J, Cortese D, Kalushkova A, Plevova K, Young E, Gunnarsson R, Falk-Sörqvist E, Lönn P, Muggen AF, Yan XJ, Sander B, Enblad G, Smedby KE, Juliusson G, Belessi C, Rung J, Chiorazzi N, Strefford JC, Langerak AW, Pospisilova S, Davi F, Hellström M, Jernberg-Wiklund H, Ghia P, Söderberg O, Stamatopoulos K, Nilsson M, Rosenquist R. Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia. *J Exp Med*. 2015 Jun;212(6):833-43. (IF: 11.99)
56. Xochelli A, Sutton LA, Agathangelidis A, Stalika E, Karypidou M, Marantidou F, Lopez AN, Papadopoulos G, Supikova J, Groenen P, Boudjogra M, Sundstrom C, Ponzoni M, Francova HS, Anagnostopoulos A, Pospisilova S, Papadaki T, Tzovaras D, Ghia P, Pott C, Davi F, Campo E, Rosenquist R, Hadzidimitriou A, Belessi C, Stamatopoulos K. Molecular evidence for antigen drive in the natural history of mantle cell lymphoma. *Am J Pathol*. 2015 Jun;185(6):1740-8. (IF: 4.05)
57. Le Garff-Tavernier M, Herbi L, de Romeuf C, Azar N, Roos-Weil D, Bonnemye P, Urbain R, Leblond V, Merle-Béral H, Vieillard V. The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia. *Haematologica*. 2015 Apr;100(4):e147-51. (IF: 7.70)
58. Baychelier F, Achour A, Nguyen S, Raphael M, Toubert A, Besson C, Arnoux A, Roos-Weil D, Marty M, Chapelier A, Samuel D, Debré P, Vieillard V; Study of Cancers After Solid Organs Transplants (K-GREF) Study Group.. Natural killer cell deficiency in patients with non-Hodgkin lymphoma after lung transplantation. *J Heart Lung Transplant*. 2015 Apr;34(4):604-12. (IF: 7.11)
59. Martinez-Torres AC, Quiney C, Attout T, Boulet H, Herbi L, Vela L, Barbier S, Chateau D, Chapiro E, Nguyen-Khac F, Davi F, Le Garff-Tavernier M, Moumné R, Sarfati M, Karoyan P, Merle-Béral H, Launay P, Susin SA. CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans. *PLoS Med*. 2015 Mar 3;12(3):e1001796. (IF: 11.86)
60. Sutton LA, Ljungström V, Mansouri L, Young E, Cortese D, Navrkalova V, Malcikova J, Muggen AF, Trbusek M, Panagiotidis P, Davi F, Belessi C, Langerak AW, Ghia P, Pospisilova S, Stamatopoulos K, Rosenquist R. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting. *Haematologica*. 2015 Mar;100(3):370-6. (IF: 7.70)
61. Michot JM, Canoni D, Driss H, Alric L, Cacoub P, Suarez F, Sibon D, Thieblemont C, Dupuis J, Terrier B, Feray C, Tilly H, Pol S, Leblond V, Settegrana C, Rabiega P, Barthe Y, Hendel-Chavez H, Nguyen-Khac F, Merle-Béral H, Berger F, Molina T, Charlotte F, Carrat F, Davi F, Hermine O, Besson C; ANRS HC-13 Lympho-C Study Group.. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. *Am J Hematol*. 2015 Mar;90(3):197-203. (IF: 5.27)
62. Valent P, Berger J, Cerny-Reiterer S, Peter B, Eisenwort G, Hoermann G, Mullauer L, Mannhalter C, Steurer M, Bettelheim P, Horny HP, Arock M. Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. *Ann Hematol*. 2015 Feb; 94(2): 223-31. (IF: 3.08)
63. Cerny-Reiterer S, Rabenhorst A, Stefanzl G, Herndlhofer S, Hoermann G, Mullauer L, Baumgartner S, Beham-Schmid C, Sperr WR, Mannhalter C, Sill H, Linkesch W, Arock M, Hartmann K, Valent P. Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. *Oncotarget*. 2015 Feb; 6(5): 3071-84 (IF: 5.16)

64. Xochelli A, Agathangelidis A, Kavakiotis I, Minga E, Sutton LA, Baliakas P, Chouvarda I, Giudicelli V, Vlahavas I, Maglaveras N, Bonello L, Trentin L, Tedeschi A, Panagiotidis P, Geisler C, Langerak AW, Pospisilova S, Jelinek DF, Oscier D, Chiorazzi N, Darzentas N, Davi F, Ghia P, Rosenquist R, Hadzidimitriou A, Belessi C, Lefranc MP, Stamatopoulos K. Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia. *Immunogenetics*. 2015 Jan;67(1):61-6. (IF: 2.09)
65. Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, Scarfo L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, Moreno D, Van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. *Blood*. 2015 Jan;125(5):856-9. (IF: 13.16)
66. Valent P, Sotlar K, Sperr WR, Reiter A, Arock M, Horny HP. Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. *Leuk Res*. 2015 Jan; 39(1): 1-5. (IF: 2.50)

## 2014

67. Trocoli A, Bensadoun P, Richard E, Labrunie G, Merhi F, Schläfli AM, Brigger D, Souquere S, Pierron G, Pasquet JM, Soubeyran P, Reiffers J, Ségal-Bendirdjian E, Tschan MP, Djavaheri-Mergny M. p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells. *Cell Death Differ*. 2014, Dec;21:1852-61. (IF: 8.33)
68. Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Nichelatti M, Tsanousa A, Scarfo L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. *Lancet Haematol*. 2014 Nov;1(2):e74-84. (IF: 7.12)
69. Kofman T, Zhang SY, Copie-Bergman C, Moktefi A, ..., Roos-Weil D, Desvaux D, Grimbert P, Haioun C, Lang P, Sahali D, Audard V. Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders: a retrospective study of 18 cases. *Medicine*. 2014 Nov;93(24):350-8. (IF: 1.80)
70. Te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, Greil R, Merkel O, Pospíšilová S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC). Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. *Br J Haematol*. 2014 Nov;167(4):565-9. (IF: 5.67)
71. Bouchet S, Tang R, Fava F, Legrand O, Bauvois B. Targeting CD13 (aminopeptidase-N) in turn downregulates ADAM17 by internalization in acute myeloid leukaemia cells. *Oncotarget*. 2014 Sep 30;5(18):8211-22. (IF: 5.16)
72. Besancenot R, Roos-Weil D, Tonetti C, Abdelouahab H, Lacout C, Pasquier F, Willekens C, Rameau P, Lecluse Y, Micol JB, Constantinescu SN, Vainchenker W, Solary E, Giraudier S. JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. *Blood*. 2014 Sep 25;124(13):2104-15. (IF: 13.16)
73. Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, Diop M, Scourzic L, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Kikushige Y, Davi F, Lambert J, Gautheret D, Merle-Béral H, Sutton L, Dessen P, Solary E, Akashi K, Vainchenker W, Mercher T, Droin N, Ogawa S, Nguyen-Khac F\*, Bernard OA\*. Acquired initiating mutations in early hematopoietic cells of CLL patients. *Cancer Discov*. 2014 Sep;4(9):1088-101. \*Senior co-authors (IF: 20.01)
74. Cosson A, Chapiro E, Belhouachi N, Cung HA, Keren B, Damm F, Algrin C, Lefebvre C, Fert-Ferrer S, Luquet I, Gachard N, Mugneret F, Terre C, Collonge-Rame MA, Michaux L, Raford-Weiss I, Talmant P, Veronese L, Nadal N, Struski S, Barin C, Helias C, Lafage M, Lippert E, Auger N, Eclache V, Roos-Weil D, Leblond V, Settegrana C, Maloum K, Davi F, Merle-Béral H, Lesty C, Nguyen-Khac F; Groupe Francophone de Cytogénétique Hématologique. 14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma. *Genes Chromosomes Cancer*. 2014 Aug;53(8):657-66. (IF: 3.69)
75. Toutou V, Bodaghi B, Thepot S, Chapiro E, Nguyen-Khac F, Charlotte F, LeHoang P, Maloum K. When the eye gives it all: diagnosis of relapsing acute myeloblastic leukemia with anterior chamber tap of a chronic hypopyon. *Am J Hematol* 2014 Aug;89:858-859. (IF: 5.275)
76. Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I, Blatt K, Hadzijušufovic E, Jeanningros S, Blanc C, Legarff-Tavernier M, Chapiro E, Nguyen-Khac F, Subra F, Bonnemye P, Dubreuil P, Desplat V, Merle-Béral H, Willmann M, Rülcke T, Valent P, Arock M. A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. *Blood*. 2014 Jul 3;124(1):111-20. (IF: 13.16)
77. Ferreira P, Villanueva R, Martinez-Julve M, Herguedas B, Marcuello C, Fernandez-Silva P, Cabon L, Hermoso JA, Lostao A, Susin SA, and Medina M. Structural insights into the coenzyme mediated monomer-

dimer transition of the pro-apoptotic Apoptosis Inducing Factor. *Biochemistry*. 2014 Jul 1;53(25):4204-15. (IF: 2.93)

78. ■ Mahendra A, Gangadharan B, André S, Boudjoghra M, Davi F, Lecerf M, Planchais C, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD. Cryptic polyreactivity of IgG expressed by splenic marginal zone B-cell lymphoma. *Mol Immunol*. 2014 Jul;60(1):54-61. (IF: 3.23)

79. Gentien D, Kosmider O, Nguyen-Khac F, Albaud B, Rapinat A, Dumont AG, Damm F, Popova T, Marais R, Fontenay M, Roman-Roman S, Bernard OA, Stern MH. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages. *Leukemia* 2014 Jun;28:1355-1357. (IF: 11.70)

80. AlQahtani A, Touitou V, Cassoux N, Aknin C, Merle-Beral H, Bodaghi B, LeHoang P. More than a masquerade syndrome: atypical presentations of vitreoretinal lymphomas. *Ocul Immunol Inflamm* 2014 Jun;22(3):189-96. (IF: 2.45)

81. Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, Kolb B, Durieu I, Gyan E, Livideanu C, Cheze S, Diouf M, Garidi R, Georgin-Lavialle S, Asnafi V, Lhermitte L, Lavigne C, Launay D, Arock M, Lortholary O, Dubreuil P, Hermine O. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. *PLoS One*. 2014 Jan; 9(1): e85362. (IF: 2.80)

82. Gendron N, Belhouachi N, Morel V, Azgui Z, Maloum K, Nguyen-Khac F, Cayuela JM, Davi F, Merle-Béral H, Chapiro E. [Chronic myeloid leukemia with variante19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up]. *Ann Biol Clin (Paris)*. 2014 May-Jun;72(3):359-66. (IF: 0.22)

83. Nguyen-Khac F, Della Valle V, Lopez RG, Ghysdael J, Bernard OA. Deregulation of AhR function by the human acute leukemia TEL-ARNT fusion protein. *Am J Hematol* 2014 May;89:566-567. (IF: 5.27)

84. Harrison CJ, Rowley JD, Van den Berghe H, Bernheim A, Martineau M, Gautier M, Le Coniat-Busson M, Romana S, Dastugue N, Hagemeyer A, Jonveaux P, Nguyen-Khac F, Bernard OA. No chromosome arm turned: in memory of Roland Berger 1934-2012. *Leukemia* 2014 May;28:464-469: discussion 469. (IF: 11.70)

85. Kakeda M, Arock M, Schlapbach C, Yawalkar N. Increased expression of heat shock protein 90 in keratinocytes and mast cells in patients with psoriasis. *J Am Acad Dermatol*. 2014 April; 70(4): 683-90 e1. (IF: 7.0)

86. Baliakas P, Iskas M, Gardiner A, Davis Z, Plevova K, Nguyen-Khac F, Malcikova J, Anagnostopoulos A, Glide S, Mould S, Stepanovska K, Brejcha M, Belessi C, Davi F, Pospisilova S, Athanasiadou A, Stamatopoulos K, Oscier D. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. *Am J Hematol* 2014 Mar;89:249-255. (IF: 5.27)

87. Chapiro E, Antony-Debre I, Marchay N, Parizot C, Lesty C, Cung HA, Mathis S, Grelier A, Maloum K, Choquet S, Azgui Z, Uzunov M, Leblond V, Merle-Beral H, Sutton L, Davi F, Nguyen-Khac F. Sex chromosome loss may represent a disease-associated clonal population in chronic lymphocytic leukemia. *Genes Chromosomes Cancer*. 2014 Mar;53(3):240-7. (IF: 3.69)

88. Baliakas P, Iskas M, Gardiner A, Davis Z, Plevova K, Nguyen-Khac F, Malcikova J, Anagnostopoulos A, Glide S, Mould S, Stepanovska K, Brejcha M, Belessi C, Davi F, Pospisilova S, Athanasiadou A, Stamatopoulos K, Oscier D. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. *Am J Hematol*. 2014 Mar;89(3):249-55. (IF: 5.27)

89. Baron M, Maloum K, Roos-Weil D. Central diabetes insipidus revealing neuromeningeal localization of chronic myelomonocytic leukaemia. *Br J Haematol*. 2014 Feb;164(3):314. (IF: 5.67)

90. Le Garff-Tavernier M, Herbi L, de Romeuf C, Nguyen-Khac F, Davi F, Grelier A, Boudjoghra M, Maloum K, Choquet S, Urbain R, Vieillard V, Merle-Béral H. Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. *Leukemia*. 2014 Jan;28(1):230-3. (IF: 11.70)

## 2013

91. Strefford JC, Sutton LA, Baliakas P, Agathangelidis A, Malcikova J, Plevova K, Scarfo L, Davis Z, Stalika E, Cortese D, Cahill N, Pedersen LB, di Celle PF, Tzenou T, Geisler C, Panagiotidis P, Langerak AW, Chiorazzi N, Pospisilova S, Oscier D, Davi F, Belessi C, Mansouri L, Ghia P, Stamatopoulos K, Rosenquist R. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. *Leukemia*. 2013 Nov;27(11):2196-9. (IF: 11.70)

92. Couronne L, Scourzic L, Pilati C, Della Valle V, Duffourd Y, Solary E, Vainchenker W, Merlio JP, Beylot-Barry M, Damm F, Stern MH, Gaulard P, Lamant L, Delabesse E, Merle-Beral H, Nguyen-Khac F, Fontenay M, Tilly H, Bastard C, Zucman-Rossi J, Bernard OA, Mercher T. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. *Haematologica* 2013 Nov;98:1748-1752. (IF: 7.70)

93. Neven B, Mamessier E, Bruneau J, Kaltenbach S, Kotlarz D, Suarez F, Masliah-Planchon J, Billot K, Canioni D, Frange P, Radford-Weiss I, Asnafi V, Murugan D, Bole C, Nitschke P, Goulet O, Casanova JL, Blanche S, Picard C, Hermine O, Rieux-Laucat F, Brousse N, Davi F, Baud V, Klein C, Nadel B, Ruemmele F,

Fischer A. A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. *Blood*. 2013 Nov 28;122(23):3713-22. (IF: 13.16)

94. Grelier A, Le Garff-Tavernier M, Nauwelaers F, Sarfati M, Merle-Beral H. Soluble CD23 measurement by CBA: A convenient and reliable quantification method in chronic lymphocytic leukemia. *Cytometry B Clin Cytom*. 2013 Oct. doi: 10.1002/cyto.b.21135. (IF: 2.47)

95. Te Raa GD, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Le Garff-Tavernier M, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC). Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. *Leuk Lymphoma*. 2013 Aug;54(8):1849-53. (IF: 2.75)

96. Piedfer M, Bouchet S, Tang R, Billard C, Dauzonne D, Bauvois B. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells. *Biochim Biophys Acta-Molecular Cell Research*. 2013 Jun;1833(6):1316-28. (IF: 3.27)

97. Guy J, Antony-Debré I, Benayoun E, Arnoux I, Fossat C, Le Garff-Tavernier M, Raimbault A, Imbert M, Maynadié M, Lacombe F, Béné MC, Wagner-Ballon O; GEIL (Groupe d'Etude Immunologique des Leucémies). Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia. *Br J Haematol*. 2013 May;161(4):551-5. (IF: 5.67)

98. Chapiro E, Radford-Weiss I, Cung HA, Dastugue N, Nadal N, Taviaux S, Barin C, Struski S, Talmant P, Vandenberghe P, Mozziconacci MJ, Tigaud I, Lefebvre C, Penther D, Bastard C, Lippert E, Mugneret F, Romana S, Bernard OA, Harrison CJ, Russell LJ, Nguyen-Khac F. Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature. *Cancer genetics* 2013 May;206:162-173. (IF: 1.93)

99. Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Andrieux J, Eclache V, Bilhou-Nabera C, Luquet I, Terre C, Baranger L, Mugneret F, Chiesa J, Mozziconacci MJ, Callet-Bauchu E, Veronese L, Blons H, Owen R, Lejeune J, Chevret S, Merle-Beral H, Leblond V. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia. *Haematologica* 2013 Apr;98:649-654. (IF: 7.70)

100. Rossi B, Epelboin L, Jauréguiberry S, Lecso M, Roos-Weil D, Gabarre J, Grenier PA, Bricaire F, Caumes E. Melioidosis and hairy cell leukemia in 2 travelers returning from Thailand. *Emerg Infect Dis*. 2013 Mar;19(3):503-5. (IF: 8.22)

101. Véronèse L, Tournilhac O, Callanan M, Prie N, Kwiatkowski F, Combes P, Chauvet M, Davi F, Gouas L, Verrelle P, Guièze R, Vago P, Bay JO, Tchirkov A. Telomeres and chromosomal instability in chronic lymphocytic leukemia. *Leukemia*. 2013 Feb;27(2):490-3. (IF: 11.70)

102. Vignier N, Amor F, Fogel P, Duvallet A, Poupot J, Charrier S, Arock M, Montus M, Nelson I, Richard I, Carrier L, Servais L, Voit T, Bonne F, Israeli D. Distinctive serum miRNA profile in mouse models of striated muscular pathologies. *PLoS One*. 2013 Feb; 8(2): e55281. (IF: 2.80)

103. Bougherara H, Georjin-Lavialle S, Damaj G, Launay JM, Lhermitte L, Auclair C, Arock M, Dubreuil P, Hermine O, Poul MA. Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications. *Clin Lymphoma Myeloma Leuk*. 2013 Feb; 13(1): 62-9. (IF: 2.49)

104. ■ Fisson S, Ouakrim H, Touitou V, Baudet S, Ben Abdelwahed R, Donnou S, Miloudi A, Galand C, Bodaghi B, Lehoang P, Brissard M, Le Garff-Tavernier M, Fridman WH, Sautès-Fridman C, Cassoux N, Merle-Béral H. Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis. *PLoS One* 2013 Feb;8(2):e52385. (IF: 2.80)

105. Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atienza A, Arcese W, Beelen DW, Cornelissen JJ, Kröger N, Milone G, Rossi G, Jardin F, Peters C; European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties.. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. *Blood*. 2013 Jan 17;121(3):440-6. (IF: 13.16)

106. Le Guennec L, Roos-Weil D, Mokhtari K, Chauvet D, Psimaras D, Reiner P, Demeret S, Bolgert F, Choquet S, Weiss N. Granulomatous angitis of the CNS revealing a Hodgkin lymphoma. *Neurology*. 2013 Jan 15;80(3):323-4. (IF: 7.59)

107. Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. *J Clin Oncol* 2013 Jan;31:301-307. (IF: 24.00)

## 2012

108. Put N, Van Roosbroeck K, Konings P, Meeus P, Brusselmans C, Rack K, Gervais C, Nguyen-Khac F, Chapiro E, Radford-Weiss I, Struski S, Dastugue N, Gachard N, Lefebvre C, Barin C, Eclache V, Fert-Ferrer S, Laibe S, Mozziconacci MJ, Quilichini B, Poirel HA, Wlodarska I, Hagemeijer A, Moreau Y, Vandenberghe P, Michaux L. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. *Annals of Hematology* 2012 Jun;91:863-873. (IF: 3.08)



109. Puissegur MP, Eichner R, Quelen C, Coyaud E, Mari B, Lebrigand K, Broccardo C, Nguyen-Khac F, Bousquet M, Brousset P. B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells. *Leukemia* 2012 Oct;26:2224-2232. (IF: 11.70)
110. Nadal N, Chapiro E, Flandrin-Gresta P, Thouvenin S, Vasselon C, Beldjord K, Fenneteau O, Bernard O, Campos L, Nguyen-Khac F. LHX2 deregulation by juxtaposition with the IGH locus in a pediatric case of chronic myeloid leukemia in B-cell lymphoid blast crisis. *Leukemia Research* 2012 Sep;36:e195-198. (IF: 2.50)
111. Perrot A, Pionneau C, Azar N, Baillou C, Lemoine FM, Leblond V, Merle-Béral H, Béné MC, Herbrecht R, Bahram S, Vallat L. Waldenström's macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders. *Blood Cancer J.* 2012 Sep 7;2:e88. (IF: 6.12)
112. Divoux A, Moutel S, Poitou C, Lacasa D, Veyrie N, Aissat A, Arock M, Guerre-Millo M, Clement K. Mast cells in human adipose tissue: link with morbid obesity, inflammatory status, and diabetes. *J Clin Endocrinol Metab.* 2012 Sept; 97(9): E1677-85. (IF: 5.45)
113. Baritaud M, Cabon L, Delavallée L, Galan-Malo P, Gilles M-E, Brunelle-Navas MN, and Susin SA. AIF-mediated caspase-independent necroptosis requires ATM and DNA-PK-induced Ser139 histone H2AX phosphorylation. *Cell Death Dis.* 2012 Sep 13;3:e390. (IF: 5.96)
114. Marino ML, Pellegrini P, Di Lernia G, Djavaheri-Mergny M, Brnjic S, Zhang X, Hägg M, Linder S, Fais S, Codogno P, De Milito A. autophagy is a protective mechanism for human melanoma cells under acidic stress. *J Biol Chem.* 2012 Aug; 287:30664-76. (IF: 4.12)
115. Drullion C, Trégoat C, Lagarde V, Tan S, Gioia R, Priault M, Djavaheri-Mergny M, Brisson A, Auberger P, Mahon FX, Pasquet JM. Apoptosis and autophagy have opposite roles on imatinib -induced K562 leukemia cell senescence. *Cell Death Dis.* 2012, Aug; 16(3):e373. (IF: 5.96)
116. Van VQ, Baba N, Wakahara K, Rubio M, Pancini B, Richard C, Soucy G, Franchimont D, Fortin G, Martinez-Torres AC, Cabon L, Susin SA, and Sarfati M. CD47Low status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice. *PLoS One*, 2012 Aug;7(8):e41972. (IF: 2.80)
117. Touitou V, Fenollar F, Cassoux N, Merle-Beral H, LeHoang P, Amoura Z, Drancourt M, Bodaghi B. Ocular Whipple's disease: therapeutic strategy and long-term follow-up. *Ophthalmology.* 2012 Jul;119(7):1465-9. (IF: 8.20)
118. Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ, Davis Z, van Gastel-Mol EJ, Tresoldi C, Chu CC, Cahill N, Giudicelli V, Tichy B, Pedersen LB, Foroni L, Bonello L, Janus A, Smedby K, Anagnostopoulos A, Merle-Beral H, Laoutaris N, Juliusson G, di Celle PF, Pospisilova S, Jurlander J, Geisler C, Tsaftaris A, Lefranc MP, Langerak AW, Oscier DG, Chiorazzi N, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. *Blood.* 2012 May;119(19):4467-75. (IF: 13.16)
119. Kostareli E, Gounari M, Janus A, Murray F, Brochet X, Giudicelli V, Pospisilova S, Oscier D, Foroni L, di Celle PF, Tichy B, Pedersen LB, Jurlander J, Ponzoni M, Kouvatsi A, Anagnostopoulos A, Thompson K, Darzentas N, Lefranc MP, Belessi C, Rosenquist R, Davi F, Ghia P, Stamatopoulos K. Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. *Leukemia.* 2012 May;26(5):1127-31. (IF: 11.70)
120. Van VQ, Raymond M, Baba N, Rubio M, Wakahara K, Susin SA, Sarfati M. CD47high Expression on CD4 Effectors Identifies Functional Long-Lived Memory T Cell Progenitors. *J Immunol.* 188(9):4249-55. *J Immunol.* 2012 May 1;188(9):4249-55. (IF 4.85)
121. Dagklis A, Ponzoni M, Govi S, Cangi MG, Pasini E, Charlotte F, Vino A, Doglioni C, Davi F, Lossos IS, Ntountas I, Papadaki T, Dolcetti R, Ferreri AJ, Stamatopoulos K, Ghia P. Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation. *Leukemia.* 2012 Apr;26(4):814-21. (IF: 11,70)
122. Tsakou E, Agathangelidis A, Boudjoghra M, Raff T, Dagklis A, Chatzouli M, Smilevska T, Bourikas G, Merle-Beral H, Manioudaki-Kavallieratou E, Anagnostopoulos A, Brüggemann M, Davi F, Stamatopoulos K, Belessi C. Partial versus productive immunoglobulin heavy locus rearrangements in chronic lymphocytic leukemia: implications for B-cell receptor stereotypy. *Mol Med.* 2012 Feb 10;18:138-45. (IF: 3.45)
123. Cabon L, Galan-Malo P, Bouharrou A, Delavallée L, Brunelle-Navas MN, Lorenzo HK, Gross A, and Susin SA. BID regulates AIF-mediated caspase-independent necroptosis by promoting BAX activation. *Cell Death Differ.* 2012 Feb;19(2):245-56. (IF: 8.33)
124. Zaher M, Tang R, Bombarda I, Merhi F, Bauvois B, Billard C. Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa. *Int J Oncol.* 2012 Jan;40(1):269-76. (IF: 3.07)

## Articles de synthèse / revues bibliographiques

2017

1. Rosenquist R, Ghia P, Hadzidimitriou A, Sutton LA, Agathangelidis A, Baliakas P, Darzentas N, Giudicelli V, Lefranc MP, Langerak AW, Belessi C, Davi F\*, Stamatopoulos K\*. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. *Leukemia*. 2017 May 12. doi: 10.1038/leu.2017.125. [Epub ahead of print]. (IF : 11.70) \* *Co-senior authors*
2. Ghamlouch H, Nguyen-Khac F, Bernard OA. Chronic lymphocytic leukaemia genomics and the precision medicine era. *Br J Haematol* 2017 Apr. doi: 10.1111/bjh.14719. [Epub ahead of print]. (IF: 5.67)
3. Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, Sperr WR, Bettelheim P, Akin C, Bauer K, George TI, Hadzijusufovic E, Wolf D, Gotlib J, Mahon FX, Metcalfe DD, Horny HP, Arock M. Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. *Leukemia*. 2017 April; 31(4): 788-97. (IF: 11,70)
4. Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, Sotlar K, Sperr WR, Escribano L, George TI, Kluin-Nelemans HC, Ustun C, Triggiani M, Brockow K, Gotlib J, Orfao A, Schwartz LB, Broesby-Olsen S, Bindslev-Jensen C, Kovanen PT, Galli SJ, Austen KF, Arber DA, Horny HP, Arock M, Metcalfe DD. Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. *Cancer Res*. 2017 March; 77(6): 1261-70. (IF: 9.12)
5. Armand M, Besson C, Hermine O, Davi F. Hepatitis C virus - Associated marginal zone lymphoma. *Best Pract Res Clin Haematol*. 2017 Mar - Jun;30(1-2):41-49. (IF 2.00)
6. Joffre C, Djavaheri-Mergny M, Patingre S, Sylvie Giuriato S. The yin and the yang of autophagy in cancer cells. *Med Sci (Paris)*. 2017 March, 33, 328-33.
7. Arock M. A new therapeutic advance for symptomatic systemic mastocytosis? *Lancet*. 2017 Feb; 389(10069): 576-8. (IF: 47.83)
8. Minnema MC, Kimby E, D'Sa S, Fornecker LM, Poulain S, Snijders TJ, Kastiris E, Kremer S, Fitsiori A, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier M, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. *Haematologica*. 2017 Jan;102(1):43-51. (IF 7.70)

## 2016

9. Daniel Klionsky et al. (including Mojgan Djavaheri-Mergny). Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition), *Autophagy*, 2016, 12(1):1-222. (IF: 8.59)
10. Monnier J, Georgin-Lavialle S, Canioni D, Lhermitte L, Soussan M, Arock M, Bruneau J, Dubreuil P, Bodemer C, Chandesris MO, Lortholary O, Hermine O, Damaj G. Mast cell sarcoma: new cases and literature review. *Oncotarget*. 2016 Dec; 7(40): 66299-309. (IF: 5.16)
11. Korfel A, Nowosielski M, Pardo-Moreno J, Penalver FJ, Buda G, Bennani H, Costopoulos M, Le Garff-Tavernier M, Soussain C, Schmid M, Orfao JA, Glantz M. How to facilitate early diagnosis of CNS involvement in malignant lymphoma. *Expert Rev Hematol*. 2016 Nov; 9(11): 1081-1091. (IF: 2.24)
12. Nguyen-Khac F, Daudignon A, Eclache V, Lafage-Pochitaloff M, Lefebvre C, Luquet I, Penther D. Cytogenetics in the management of hematologic malignancies: an update by the Groupe francophone de cytogenetique hematologique (GFCH). *Annales de Biologie Clinique* 2016 Oct;74:509-510. (IF: 0.22)
13. Nguyen-Khac F, Borie C, Callet-Bauchu E, Eclache V, Struski S. Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogenetique hematologique (GFCH). *Annales de Biologie Clinique* 2016 Oct; 74:561-567. (IF: 0.22)
14. Ustun C, Arock M, Kluin-Nelemans HC, Reiter A, Sperr WR, George T, Horny HP, Hartmann K, Sotlar K, Damaj G, Hermine O, Verstovsek S, Metcalfe DD, Gotlib J, Akin C, Valent P. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. *Haematologica*. 2016 Oct; 101(10): 1133-43. (IF: 7.70)
15. Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. *Biol Blood Marrow Transplant*. 2016 Aug; 22(8): 1348-56. (IF: 4.70)
16. Roos-Weil D, Nguyen-Khac F, Bernard OA. Chronic lymphocytic leukemia: Time to go past genomics? *Am J Hematol*. 2016 May; 91(5):518-28. (IF: 5.27)
17. Thieblemont C, Molina T, Davi F. Optimizing therapy for nodal marginal zone lymphoma. *Blood*. 2016 Apr;127(17):2064-71. (IF: 13.16)
18. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, Matito A, Broesby-Olsen S, Siebenhaar F, Lange M, Niedoszytko M, Castells M, Oude Elberink JN, Bonadonna P, Zanotti R, Hornick JL, Torrelo A, Grabbe J, Rabenhorst A, Nedoszytko B, Butterfield JH, Gotlib J, Reiter A, Radia D, Hermine O, Sotlar K, George TI, Kristensen TK, Kluin-Nelemans HC, Yavuz S, Hagglund H, Sperr WR, Schwartz LB, Triggiani M, Maurer M, Nilsson G, Horny HP, Arock M, Orfao A, Metcalfe DD, Akin C, Valent P. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. *J Allergy Clin Immunol*. 2016 Jan; 137(1): 35-45. (IF: 13.08)
19. Arock M. Mast cell differentiation: still open questions? *Blood*. 2016 Jan; 127(4): 373-4. (IF: 13.16)

## 2015

20. Villar VH, Merhi F, Djavaheri-Mergny M, Durán RV. Glutaminolysis and autophagy in cancer. **Autophagy**. 2015;11:1198-208. (IF: 8.59)
21. Basse C, Arock M. The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment. **Int J Cancer**. 2015 Dec; 137(12): 2785-94. (IF: 6.51)
22. Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, Kristensen TK, Kluin-Nelemans HC, Hermine O, Dubreuil P, Sperr WR, Hartmann K, Gotlib J, Cross NC, Haferlach T, Garcia-Montero A, Orfao A, Schwaab J, Triggiani M, Horny HP, Metcalfe DD, Reiter A, Valent P. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. **Leukemia**. 2015 June; 29(6): 1223-32. (IF: 11.70)
23. Arock M, Akin C, Hermine O, Valent P. Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. **Eur J Haematology**. 2015 June; 94(6): 474-90. (IF 2.65)

## 2014

24. Ségal-Bendirdjian E, Tschan, M.P, Reiffers J. and Djavaheri-Mergny M. Pro-survival role of p62/SQSTM1 during ATRA-induced granulocytic differentiation of AML cells. **Molecular Cellular Oncology**, 2014, Dec; 1(4): e970066.
25. Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink JN, Kristensen T, Butterfield JH, Triggiani M, Alvarez-Twose I, Reiter A, Sperr WR, Sotlar K, Yavuz S, Kluin-Nelemans HC, Hermine O, Radia D, van Doormaal JJ, Gotlib J, Orfao A, Siebenhaar F, Schwartz LB, Castells M, Maurer M, Horny HP, Akin C, Metcalfe DD, Arock M. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. **Allergy**. 2014 Oct; 69(10): 1267-74. (IF: 7.36)
26. Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A, George TI, Kluin-Nelemans HC, Hermine O, Butterfield JH, Hagglund H, Ustun C, Hornick JL, Triggiani M, Radia D, Akin C, Hartmann K, Gotlib J, Schwartz LB, Verstovsek S, Orfao A, Metcalfe DD, Arock M, Horny HP. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. **Ann Oncol**. 2014 Sept; 25(9): 1691-700. (IF: 11.85)
27. Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O, Damaj G, Dubreuil P, Arock M. Molecular defects in mastocytosis: KIT and beyond KIT. **Immunol Allergy Clin North Am**. 2014 May; 34(2): 239-62.
28. Bibi S, Arslanhan MD, Langenfeld F, Jeanningros S, Cerny-Reiterer S, Hadzijusufovic E, Tchertanov L, Moriggl R, Valent P, Arock M. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. **Haematologica**. 2014 March; 99(3): 417-29. (IF: 7.70)
29. Bouchet S, Bauvois B. Neutrophil Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in Leukaemias. **Cancers (Basel)**. 2014 Apr;6(2):796-812.

## 2013

30. Ferreira P, Villanueva R, Cabon L, Susín SA, Medina M. The oxido-reductase activity of the apoptosis inducing factor: a promising pharmacological tool? **Curr Pharm Des**. 2013;19(14):2628-36. (IF 2.61)
31. Cabon L, Martinez-Torres AC, and Susín SA. La mort cellulaire programmée ne manque pas de vocabulaire. **Med Sci (Paris)**. 2013 Dec;29(12):1117-24.
32. Sutton LA, Agathangelidis A, Belessi C, Darzentas N, Davi F, Ghia P, Rosenquist R, Stamatopoulos K. Antigen selection in B-cell lymphomas--tracing the evidence. **Semin Cancer Biol**. 2013 Dec;23(6):399-409. (IF: 9.14)
33. Valent P, Sperr WR, Sotlar K, Reiter A, Akin C, Gotlib J, Horny HP, Arock M. The serum tryptase test: an emerging robust biomarker in clinical hematology. **Expert Rev Hematol**. 2014 Oct; 7(5): 683-90. (IF 2.24)
34. Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, Kluin-Nelemans H, Hartmann K, Sperr WR, Brockow K, Schwartz LB, Orfao A, Deangelo DJ, Arock M, Sotlar K, Horny HP, Metcalfe DD, Escribano L, Verstovsek S, Tefferi A, Valent P. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. **Blood**. 2013 March; 121(13): 2393-401. (IF: 13.16)
35. Billard C, Merhi F, Bauvois B. Mechanistic insights into the antileukemic activity of hyperforin. **Curr Cancer Drug Targets**. 2013 Jan;13(1):1-10. (IF: 2.99)

## 2012

36. Klionsky DJ et al. (including M. Djavaheri-Mergny M) Guidelines for the use and interpretation of assays for monitoring autophagy. **Autophagy**. 2012, 8:445-544. (IF: 8.59)

37. Valent P, Klion AD, Rosenwasser LJ, Arock M, Bochner BS, Butterfield JH, Gotlib J, Haferlach T, Hellmann A, Horny HP, Leiferman KM, Metzgeroth G, Matsumoto K, Reiter A, Roufosse F, Rothenberg ME, Simon HU, Sotlar K, Vandenberghe P, Weller PF, Gleich GJ. ICON: Eosinophil Disorders. *World Allergy Organ J*. 2012 Dec; 5(12): 174-81.
38. Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escibano L, Gleixner KV, Grattan C, Hadzizujufovic E, Hagglund H, Hermine O, Horny HP, Kluin-Nelemans HC, Maurer M, Niedoszytko M, Nedoszytko B, Nilsson G, Oude-Elberink HN, Orfao A, Radia D, Reiter A, Siebenhaar F, Sotlar K, Sperr WR, Triggiani M, VanDoormaal JJ, Varkonyi J, Yavuz S, Hartmann K. European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. *Wien Klin Wochenschr*. 2012 Dec; 124(23-24): 807-14.
39. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wohrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C. Cancer stem cell definitions and terminology: the devil is in the details. *Nat Rev Cancer*. 2012 Nov; 12(11): 767-75. (IF: 37.14)
40. Langerak AW, Groenen PJ, Brüggemann M, Beldjord K, Bellan C, Bonello L, Boone E, Carter GI, Catherwood M, Davi F, Delfau-Larue MH, Diss T, Evans PA, Gameiro P, Garcia Sanz R, Gonzalez D, Grand D, Hakansson A, Hummel M, Liu H, Lombardia L, Macintyre EA, Milner BJ, Montes-Moreno S, Schuurhuis E, Spaargaren M, Hodges E, van Dongen JJ. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. *Leukemia*. 2012 Oct;26(10):2159-71. (IF: 11.70)
41. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Haferlach T, Simon HU, Reiter A, Gleich GJ. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. *J Allergy Clin Immunol*. 2012 Sept; 130(3): 607-12 e9. (IF: 13.08)
42. Damm F, Nguyen-Khac F, Fontenay M, Bernard OA. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies. *Leukemia* 2012 Sep;26:2027-2031. (IF 11.70)
43. Damm F, Nguyen-Khac F, Kosmider O, Fontenay M, Bernard OA. [Mutations in genes involved in splicing in human malignancies]. *Med/Sci (Paris)* 2012 May;28:449-453.
44. Valent P, Gleich GJ, Reiter A, Roufosse F, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Sotlar K, Butterfield JH, Cerny-Reiterer S, Mayerhofer M, Vandenberghe P, Haferlach T, Bochner BS, Gotlib J, Horny HP, Simon HU, Klion AD. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. *Expert Rev Hematol*. 2012 April; 5(2): 157-76. (IF: 2.24)
45. Thieblemont C, Davi F, Noguera ME, Brière J, Bertoni F, Zucca E, Traverse-Glehen A, Felman P, Berger F, Salles G, Coiffier B. Splenic marginal zone lymphoma: current knowledge and future directions. *Oncology (Williston Park)*. 2012 Feb;26(2):194-202. (IF: 2.26)
46. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. *Biochim Biophys Acta-Reviews On Cancer*. 2012 Jan;1825(1):29-36. (IF: 9.45)

## Editoriaux

### 2017

Sutton LA, Hadzidimitriou A, Baliakas P, Agathangelidis A, Langerak AW, Stilgenbauer S, Pospisilova S, Davis Z, Forconi F, Davi F, Ghia P, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC). Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. *Haematologica*. 2017 Jun;102(6):968-971. (IF: 7.70)

### 2014

Bauvois B. Pro-matrix metalloproteinase-9 in tumor B lymphocytes: balancing migration and homing. *J Leukoc Biol*. 2014 Aug;96(2):164-6. (IF 4.01)

Rosenquist R, Davi F, Ghia P. The microenvironment in lymphomas--dissecting the complex crosstalk between tumor cells and 'by-stander' cells. *Semin Cancer Biol*. 2014 Feb;24:1-2. (IF: 9.14)

### 2013

Rosenquist R, Davi F, Stamatopoulos K. Antigens in lymphoma development--current knowledge and future directions. *Semin Cancer Biol*. 2013 Dec;23(6):397-8. (IF: 9.14)

## Autres articles (articles publiés dans des revues professionnelles ou techniques, etc.)

### 2017

Villemonteix J, Costopoulos M, Maloum K, Leblond V, Le Garff-Tavernier M. Ouvrons l'œil ! Une localisation atypique de lymphome T/NK. *Revue Francophone des Laboratoires*, Volume 2017 March, 490:74-76.

**2016**

Costopoulos M, Le Garff-Tavernier M. Immunophénotypage des hémopathies malignes par cytométrie en flux - 22/09/16[13-000-L-10] - Doi : 10.1016/S1155-1984(16)68183-9. EMC, Sept 2009

**2015**

Costopoulos M, Maloum K. Diagnostic paraclinique d'une méningite lymphomateuse. Correspondances en Onco-Hématologie, March 2015

Morin A, Musset L, Costopoulos M, Mokhtari K, Charlotte F, Choquet S, Hoang-Xuan K. Le syndrome de Bing-Neel, Correspondances en Onco-Hématologie, March 2015

**2014**

Nguyen-Khac F. La leucémie prolymphocytaire B. Horizons Hémato. Volume 4 (2014)

**2013**

Costopoulos M, Le Garff-Tavernier M. Immunophénotypage lymphocytaire dans les syndromes lymphoprolifératifs chroniques. EMC-90-15-0121-A

Le Garff-Tavernier M, Costopoulos M, Merle-Béral H. Place de la cytométrie en flux dans le diagnostic et le suivi des syndromes lymphoprolifératifs B. Revue Francophone des laboratoires - May 2013. N° 452, p.37-48

Leblond V, Maloum K, Le Garff-Tavernier M, Davi F, Nguyen-Khac F. La maladie de Waldenström ou macroglobulinémie. Revue Francophone des laboratoires - May 2013. N° 452, p. 73-82

Bourée P, Costopoulos M. Conduite à tenir devant une onychomycose. Entretiens de Bichat 2009, volume Médecine, p. 133-135.

Nguyen-Khac F. Lymphomes T et Maladie de Hodgkin. Laboratoire pharmaceutique Pfizer. 2013

Aurrant T, Callet-Bauchu E, Cymbalista F, Delmer A, Dreyfus B, Nguyen-Khac F, Leblond V, Lepretre S, Levy V, Raynaud S, Troussard X. Recommandations 2012 de la SFH pour le diagnostic, le traitement et le suivi de la leucémie lymphoïde chronique Volume 19, supplément 1, Jan 2013

**2. Ouvrages****Monographies et ouvrages scientifiques, éditions critiques, traductions****2016**

Merle-Béral H. 17 femmes prix Nobel de sciences. Ed. Odile Jacob. Sept 2016.

**Direction / édition scientifique**

Sans objet

**Chapitres d'ouvrage****2016**

Nguyen-Khac F. Cytogenetics in Waldenström Macroglobulinemia, ISBN 978-3-319-22583-8, Edited by Springer, p. 49-51. 2016

Airiau K and Djavaheri-Mergny M. Crosstalk between the autophagy and death receptor signalling pathways, Prof. M.A Hayat Editor, Book Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging (ISBN: 978-0-12-805421-5) 2016, Vol. 10, Chapter 4; p. 119-133. 2016

Airiau K and Djavaheri-Mergny M. The Complex Crosstalk Between Autophagy and ROS Signalling Pathways. M.C. Maiuri, D. De Stefano (eds.), Autophagy Networks in Inflammation. Progress in Inflammation Research, DOI 10.1007/978-3-319-30079-5-3. 2016.

**2014**

Fontenay M, Nguyen-Khac F. Le syndrome mononucléosique. Abrégés en hématologie. Elsevier Masson. 2014

### 2013

F Ferreira P, Villanueva R, Uson A, Miramar MD, Susin SA, Peleato ML, Medina M. *Unraveling the rôle of the reductase activity of the human Apoptosis-Inducing Factor. Flavins and Flavoproteins*, pp 35-66. Eds. S. Miller, R. Hille, B. Palfey. ISBN: 9781300786405.

### 2012

Delic J, Marteau J-B, Maloum K, Nguyen-Khac F, Davi F, Azgui Z, Leblond V, Binet J-L, Chevillard S and Merle-Béral H. DNA Damage Response/Signaling and Genome (In)Stability as the New Reliable Biological Parameters Defining Clinical Feature of CLL, Chronic Lymphocytic Leukemia, ISBN 978-953-307-881-6, edited by Pablo Oppezzo, p. 63-94. 2012

Langerak AW, Rosenquist R, Ghia P, Belessi C, Stamatopoulos K, Davi F, for the ERIC-IgCLL group. Studies of rearrangements and somatic hypermutation of IGHV genes in chronic lymphocytic leukemia. In: Witt M, Dawidowska M, Szczepanski T, editors. *Molecular Aspects of Hematologic Malignancies - Diagnostic Tools and Clinical Applications*, Springer, p. 429-442. 2012

### Thèses publiées / éditées

#### 2016

Siham Bibi. Nouvelles approches thérapeutiques au cours des mastocytoses systémiques avancées KIT D816V+ résistantes aux inhibiteurs de tyrosine kinases. Université Paris XI. (Supervisor: Arock M)

Ghaith Wedeh. Identification of BRD4 as a new therapeutic target in the treatment of aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). Université Paris XI. (Supervisor: Arock M)

#### 2015

Florent Angenfeld. Apport de la modélisation et des simulations de dynamique moléculaire à la description de STAT5 comme cible pour moduler la signalisation oncogénique. Aspects cellulaires et moléculaires de la biologie. Université Paris XI. (Supervisors: Tcheranov L and Arock M)

Adrien Cosson. Caractérisation d'anomalies cytogénétiques et moléculaires dans la leucémie lymphoïde chronique. UPMC-Paris 6. (Supervisors: Susin SA and Nguyen-Khac F)

#### 2014

Carole Bourdin. Evaluation de la sensibilité d'une technique de détection rapide de la mutation du gène NOTCH1 dans la leucémie lymphoïde chronique et étude de la prévalence de la mutation de ce gène. (Supervisor: Davi F)

Lauriane Cabon. Implication d'AIF dans la mort cellulaire et la physiologie mitochondriale: Exemples dans la nécroptose intrinsèque et l'hématopoïèse. UPMC-Paris 6. (Supervisor: Susin SA)

#### 2013

Rosine Saleh. Mise en évidence de nouvelles lignées mastocytaires humaines exprimant un récepteur aux IgE fonctionnel et différents types de récepteurs KIT, utilisées comme modèles d'étude de l'allergie et des mastocytoses. *Biologie cellulaire et Moléculaire*. Université Paris XI. (Supervisor: Arock M)

Mathieu Baritaud. Etude de la dualité d'AIF, dans la mort cellulaire programmée indépendante des caspases *via* son partenaire  $\gamma$ H2AX et dans la phosphorylation oxydative *via* les complexes et supercomplexes mitochondriaux. UPMC-Paris 6. (Supervisor: Susin SA)

Ana-Carolina Martinez-Torres. Study of the mechanisms regulating CD47-mediated programmed cell death in chronic lymphocytic leukemia: the key rôle of PLC $\gamma$ 1 and calcium signaling. UPMC-Paris 6. (Supervisor: Susin SA)

Aurore Trocoli. Etude de la régulation de l'autophagie au cours de la différenciation des cellules de leucémie aiguë promyélocytaire: rôles dans la survie et la différenciation cellulaires. Université Bordeaux Segalen. (Supervisor: Djavaheri-Mergny M)

## 2012

Marion Piedfer. Identification de nouvelles cibles pro-apoptotiques dans les leucémies aiguës myéloblastiques. Médecine humaine et pathologie. Université René Descartes - Paris V. (Supervisor: Bauvois B)

Carolina Phan: Détection des mutations de TP53 dans le cadre de la leucémie lymphoïde chronique par polymérase chain reaction-high resolution melting (PCR-HRM) (Supervisor: Davi F)

Hanan Boujrad. Mort cellulaire programmée indépendante des caspases médiée par la protéine AIF : rôle de l'histone H2AX et de sa forme phosphorylée gH2AX. UPMC-Paris 6. (Supervisor: Susin SA)

Magali Le Garff-Tavernier. Impact des cellules NK dans le traitement de la Leucémie Lymphoïde Chronique et de la maladie de Waldenström par anticorps anti-CD20 optimisés. UPMC-Paris 6. (Supervisors: Merle-Béral H and Vieillard V)

## Colloques / congrès, séminaires de recherche

*The team presented about 65 abstracts and oral communications at international and national conferences. Additionally, 75 communications in international and national conferences were published in prestigious hematological journals, such as Blood or Haematologica.*

## Éditions d'actes de colloques / congress

## 2017

### Posters

E Chapiro, C Lesty, C Gabillaud, E Durot, S Struski, A Bidet, E Laharanne, C Barin, L Veronese, V Eclache, B Gaillard, L Michaud, C Lefebvre, JB Gaillard, C Terre, D Penther, C Bastard, N Nadal, S Fert-Ferrer, N Auger, C Godon, O Tournilhac, L Sutton, F Nguyen-Khac. Isochromosome 17q, unbalanced translocations and 8q gain represent adverse prognostic factors in chronic lymphocytic leukemia (CLL) with 17p deletion, a GFCH study. 17<sup>th</sup> International Workshop on Chronic Lymphocytic Leukemia (iwCLL), New York, USA, May 2017 (abstract 117); 22<sup>nd</sup> European Hematology Association (EHA) congress, Madrid, June 2017 (abstract 1966)

B Gaillard, P Cornillet-Lefebvre, K Maloum, M Pannetier, C Lecoq-Lafon, C Gabillaud, C Lesty, N Nadal, A Ittel, S Struski, C Lefebvre, JB Gaillard, M Lafage, E Balducci, C Barin, MA Collonge-Rame, S Richebourg, P Lemaire, S Defasque, I Radford-Weiss, F Nguyen-Khac, E Chapiro. Clinicobiological features of B-cell neoplasms with CDK6 translocations: frequent association with marginal-zone lymphoma, contingent of polyclonal cells and TP53 abnormalities. A GFCH study. 22<sup>nd</sup> European Hematology Association (EHA) congress, Madrid, June 2017 (abstract 3235)

Roos-Weil D, J Lambert, N Droin, F Damm, R Guieze, M'boypa Diop, P Feugier, S Leprêtre, X Troussard, V Ribrag, S Vaudaux, S Delepine, S Raynaud, J Lejeune, C Lesty, OA Bernard, F Nguyen-Khac. Targeted Sequencing for Clinical Investigation in Chronic Lymphocytic Leukemia. iwCLL 2017 (abstract 314)

Osman J, Tarfi S, Armand M, Caroline Houillier C, Sylvain Choquet S, Agnelo H, Strub H, Bonnemye P, Khe Hoang-Xuan K, Le Garff-Tavernier M, Costopoulos M, Davi F. Detecting malignant B-cells in cerebrospinal fluid: does the ideal method exist ? 22<sup>nd</sup> European Hematology Association (EHA) congress, Madrid, June 2017

Michallet A-S, Marie Sarah Dilhuydy, Rouille Valerie, Beatrice Mahe, Kamel Laribi, Bruno Villemagne, Gilles Salles, Olivier Tournilhac, Alain Delmer, Christelle Portois, Brigitte Pegourie, Veronique Leblond, Cecile Tomowiak, Sophie De Guibert, Frederique Orsini-Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc-Matthieu Fornecker, Ysebaert Loic, Caroline Dartigeas, Margot Truchan, Magali Le Garff Tavernier, Therese Aurrant-Schleinitz, Florence Cymbalista, Stephane Lepretre, Vincent Levy, Carmen Aanei, Michel Ticchioni, Remi Letestu, Pierre Feugier. Phase II, Multicenter Trial, Exploring "Chemo-Sparing" Strategy Associating Obinutuzumab+ibrutinib Followed By an MRD Driven Strategy, In Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results. 17<sup>th</sup> International Workshop on Chronic Lymphocytic Leukemia (iwCLL), New York, USA, May 2017

Ahle G, Inès Harzallah; Magali Le Garff-Tavernier; Myrto Costopoulos; Remy Hurstel; Bernard Drénou; Agathe Debliquis. Plus que jamais ! L'importance du LCR pour le diagnostic de lymphome oculocérébral Journées de Neurologie de Langue Française (JNLF), Toulouse, France, March 2017

Osman J, Sihem Tarfi , Caroline Houillier , Sylvain Choquet , Hervé Agnelo , Hervé Strub , Patrick Bonnemye, Magali Le Garff-Tavernier, Frederic Davi, Marine Armand, Myrto Costopoulos. Comparaison de la biologie moléculaire et de la cytométrie en flux pour la mise en évidence d'une dissémination méningée lymphomateuse. 37<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2017

Le Garff-Tavernier M, Agathe Debliquis, Rémi Letestu, Bernard Chatelain, Régis Peffault de Latour, Bernard Drenou, Oriane Wagner-Ballon. Observatoire National des clones HPN : bilan après 1 an d'inclusions. 37<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2017

#### Oral communications

Tournilhac O, Le Garff Tavernier Magali, Reza Tabrizi, Stephanie Nguyen, Lionel Mannone, Patrice Chevallier, Oumedy Reman, Tomowiak Cecile, Cecile Borel, Sylvie Francois, Pascal Turlure, Sebastien Maury, Gaëlle Guillerm, Laure Vincent, Luc-Matthieu Bilger, Richard Lemal, Claire Quiney, Lauren Veronese, Aurelie Cabrespine, Jacques-Olivier Bay, Veronique Leblond, Nathalie Dhedin. RIC allogeneic stem cell transplantation for high risk CLL followed by preemptive MRD-based immunointervention - Final results from the phase II ICLL03 RICAC-PMM trial (FILO - SFGM-TC French intergroup). 17<sup>th</sup> International Workshop on Chronic Lymphocytic Leukemia (iwCLL), New York, May 2017

Le Garff-Tavernier M, Oriane Wagner-Ballon. Observatoire National des clones HPN : bilan après 1 an d'inclusions. 37<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2017

Pramil E, Herbi L, Merle-Béral H, Karoyan P, Susin SA. Mort cellulaire programmée induite par des peptides agonistes du récepteur CD47: une nouvelle stratégie pour le traitement de la leucémie lymphoïde chronique. 37<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2017

Costopoulos M., Ronez E. Les hémopathies lymphoïdes: du classique à l'atypique. 7<sup>th</sup> Syndicat des Biologistes du Liban Congress, Beyrouth, Liban, March 2017

Costopoulos M, Place de la cytométrie en flux pour le diagnostic des leucémies aiguës - 7<sup>th</sup> Syndicat des Biologistes du Liban Congress, Beyrouth, Liban, March 2017

## 2016

#### Posters

Roos-Weil D, J Lambert, N Droin, F Damm, R Guieze, M'boypa Diop, P Feugier, S Leprêtre, X Troussard, V Ribrag, S Vaudaux, S Delepine, S Raynaud, J Lejeune, C Lesty, OA Bernard, F Nguyen-Khac. Targeted Sequencing for Clinical Investigation in Chronic Lymphocytic Leukemia. ASH, December 2016 (abstract 3202)

Letestu R, Magali Le Garff-Tavernier, Chantal Fossat, Agathe Debliquis, Claire Loosen, Oriane Wagner-Ballon, Benoît Lesquerbault, Bernard Chatelain, Bernard Drenou. Etude nationale Multicentrique, Multiplateforme et Multicolore pour la détection de l'Hémoglobineurie Paroxystique Nocturne (HPN): adhérer à la procédure dans l'étude «3M». 36<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2016

Dahmani A, Christine Arnoulet, Lucile Baseggio, Lydia Campos-Guyotat , Bernard Chatelain, Agathe Debliquis, Bernard Drenou, Marie-Christine Jacob, Eric Legac, Magali Le Garff-Tavernier, Claire Quiney, Nelly Robillard , Françoise Solly, Michel Ticchioni, Guillaume Cartron , Caroline Dartigeas, Pierre Feugier , Véronique Leblond, Stéphane Lepretre, Eric Van Den Neste, Marie-Hélène Delfau-Larue, Florence Cymbalista, Rémi Letestu. Développements récents dans la détection de la maladie résiduelle (MRD) par cytométrie en flux 6 et 8 couleurs dans la leucémie lymphoïde chronique (LLC). 36<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2016

Kim R, Myrto Costopoulos, Sylvain Choquet, Karim Maloum, Caroline Algrin, Caroline Houillier, Catherine Settegrana, Juliette Villemonteix, Frédéric Davi, Véronique Leblond, Hélène Merle-Béral, Magali Le Garff-Tavernier. "To Dose or not to Dose ?" IL-10 et IL-6 : biomarqueurs d'intérêt pour le diagnostic des localisations méningées des lymphoproliférations B systémiques à petites cellules? 36<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2016

Cabon L, Bertaux A, Brunelle-Naval M-N, and Susin SA. AIF influences hematopoiesis by regulating mitochondrial OXPHOS and metabolism. Keystone Symposia : Immunometabolism in Immune Function and Inflammatory Disease. Alberta, Canada. February 2016

#### Oral communications

Le Garff-Tavernier M, Oriane Wagner-Ballon. Point sur l'Observatoire National des Clones HPN. Oral 20<sup>th</sup> Association Française de Cytométrie (AFC) Congress, Montpellier, France, November 2016

Roos-Weil D, D Lara, V Della-Valle, E Durot, M Diop, F Damm, N Azar, V Leblond, V Ribrag, V Clayette, R Haddad, N Droin, F Pflumio, F Nguyen-Khac, OA Bernard. Molecular abnormalities in Waldenström's macroglobulinemia. International Workshop on Waldenström Macroglobulinemia (IWWM), October 2016



Le Garff-Tavernier M. Intérêt de l'immunophénotypage au cours des SMD. 3<sup>ème</sup> Congrès International Francophone de Biologie Clinique et Médecine de Laboratoire, 16<sup>èmes</sup> Journées Marocaines de Biologie Clinique, Rabat, Maroc, June 2016

Djavaheri-Mergny M. A G-quadruplex ligand induces autophagy and impairs cancer cell division. International cell death society (ICDS), cell death and its translational ramification Cork Ireland, 2- 4 June 2016

Le Garff-Tavernier M, Fanny Baran-Marszak. P53 dans tous ses états. 36<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2016

## 2015

### Posters

Rathana Kim, Myrto Costopoulos, Sylvain Choquet, Karim Maloum, Caroline Algrin, Khe Hoang-Xuan, Catherine Settegrana, Juliette Villemonteix, Martine Brissard<sup>1</sup>, Frederic Davi, Veronique Leblond, Helene Merle-Beral and Magali Le Garff-Tavernier. To Dose or Not to Dose: Are IL-10 and IL-6 Accurate Biomarkers to Detect Leptomeningeal Involvement in Small B-Cell Lymphoproliferation? 57<sup>th</sup> American Society of Hematology (ASH) Congress, Orlando, FL, USA, December 2015

Tournilhac O, Le Garff-Tavernier M, Tabrizi R, Nguyen quoc S, Legrand-Izadifar F, Chevallier P, Reman O, Tomowiak C, Cecile Borel, Sylvie Francois, Pascal Turlure, Sebastien Maury, Gaelle Guillerm, Luc Fornecker, Richard Lemal, Claire Quiney, Carole Bellanger, Laure Calvet, Veronese L, Aurelie Cabrespine, Mathieu Coudert, Jacques-Olivier Bay, Helene Merle-Beral and Nathalie Dhedin. RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Intermediate Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO & SFGM-TC French intergroup) 57<sup>th</sup> American Society of Hematology (ASH) Congress, Orlando, FL, USA, December 2015

Le Garff-Tavernier M, Rémi Letestu, Chantal Fossat, Agathe Debliquis, Claire Loosen, Oriane Wagner-Ballon, Benoît Lesquerbault, Bernard Chatelain, Bernard Drénou. Etude nationale Multicentrique, Multiplateforme et Multicolore pour la détection de l'Hémoglobininurie Paroxystique Nocturne (HPN) : adhérer à la procédure dans l'étude «3M». 19<sup>th</sup> Association Française de Cytométrie (AFC) Congress, Antibes Juan-Les-Pins, France, November 2015

Cosson A, Chapiro E, Lambert J, Cung H-A, Algrin C, Damm F, Gabillaud C, Davi F, Merle-Béral H, Choquet S, Uzunov M, Morel V, Leblond V, Maloum K, Leprêtre S, Feugier P, Lesty C, Lejeune J, Sutton L, Susin SA, Nguyen-Khac F. The gain of the short arm of chromosome 2 (2p) in Chronic Lymphocytic Leukemia (CLL) results in XPO1 overexpression and drug resistance. 20<sup>th</sup> European Hematology Association (EHA) congress, Vienna, June 2015

Costopoulos M, Belleville T, Settegrana C, Maloum K, Azgui Z, Brissard M, Bonnemye P, Choquet S, Hoang-Xuan K, Leblond V, Merle-Béral H, Le Garff-Tavernier M. Flow cytometry immunophenotyping and cytological analyses of CSF : a comparison of performances for lymphomatous cell detection. 20<sup>th</sup> European Hematology Association (EHA) congress, Vienna, June 2015

Belleville T, M Costopoulos, K Maloum, C Settegrana, Z Azgui, M Brissard, P Bonnemye, S Choquet, K Hoang-Xuan, V Leblond, H Merle-Béral, M Le Garff-Tavernier. Comparaison de la cytologie et du phénotypage par cytométrie en flux dans le LCR pour la détection des cellules lymphomateuses. 35<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2015

Martinez-Torres AC, Quiney C, Attout T, Boulet H, Herbi L, Vela L, Barbier S, Chateau D, Chapiro E, Nguyen-Khac F, Davi F, Le Garff-Tavernier M, Moumné R, Sarfati M, Karoyan P, Merle-Béral H, Launay P, Susin SA. CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCg1 activation: evidence from mice and humans. 35<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2015

### Oral communications

Roos-Weil D, P Feugier, S Llepretre, S Chevret, K Diop, R Delepine, R Guièze, V Ribrag, S Raynaud, X Troussard, N Droin, O Bernard, F Nguyen-Khac. Analyse moléculaire par séquençage à haut débit ciblé de 161 LLC non traitées incluses dans un protocole prospectif. Congrès de la Société Française d'Hématologie, Paris 2015.

Cosson A, E Chapiro, J Lambert, H-A Cung, C Algrin, F Damm, C Gabillaud, F Davi, H Merle-Béral, S Choquet, M Uzunov, V Morel, V Leblond, S Leprêtre, P Feugier, C Lesty, J Lejeune, L Sutton, S A. Susin, F Nguyen-Khac. Le gain du bras court du chromosome 2 (2p) entraîne une résistance aux traitements dans la Leucémie Lymphoïde Chronique (LLC). Congrès de la Société Française d'Hématologie, Paris 2015. (séance plénière)

Guièze R, P Robbe, R Clifford, S De Guibert, A Timbs, MS Dilhuydy, M Cebes, L Ysebaert, A Burns, F Nguyen Khac, F Davi, L Véronèse. Spectre mutationnel de la leucémie lymphoïde chronique réfractaire ou en rechute : un profil à plusieurs événements. Congrès de la Société Française d'Hématologie, Paris 2015.

A Cosson, E Chapiro, J Lambert, H-A Cung, C Algrin, F Damm, C Gabillaud, F Davi, H Merle-Béral, S Choquet, M Uzunov, V Morel, V Leblond, S Leprêtre, P Feugier, C Lesty, J Lejeune, L Sutton, S A Susin, F Nguyen-Khac. The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia. Congress of American Society of Hematology, Orlando

Le Garff-Tavernier M, Letestu R, Fossat C, Debliquis A, Claire Loosen, Wagner-Ballon O, Lesquerbault B, Chatelain B, Drénou B. Pour le groupe HPN-AFC Etude nationale Multicentrique, Multiplateforme et Multicolore pour la détection de l'Hémoglobininurie Paroxystique Nocturne (HPN): adhérer à la procédure dans l'étude «3M». 19<sup>th</sup> Association Française de Cytométrie (AFC) Congress, Antibes Juan-Les-Pins, France, November 2015

Le Garff-Tavernier M. Lymphomes extranodaux : Explorations biologiques dans le LCR et les liquides oculaires. 19<sup>th</sup> Association Française de Cytométrie (AFC) Congress, Antibes Juan-Les-Pins, France, November 2015

Letestu R, Le Garff-Tavernier M, Fossat C, Debliquis A, Loosen C, Wagner-Ballon O, Lesquerbault B, Chatelain B, Drénou B on behalf of the French PNH-AFC study group. Multicolor-Multiplatform-Multicenter experience on Paroxysmal Nocturnal Hemoglobinuria (PNH) clone detection by flow-cytometry: sticking with the procedure in "the 3M study". European Society for Clinical Cell Analysis (ESCCA) Congress, Catania, Sicily, September 2015

Tournilhac O, Milpied N, Le Garff-Tavernier M, Nguyen Quoc S, Legrand F, Reman O, Chevallier P, Tomowiak C, Borel C, R Lemal, Francois S, Brest, Montpellier, Limoges, Strasbourg, Quiney C, Bellanger C, Calvet L, Veronese L, Cabrespine A, statisticien PS, Merle-Beral H, Dhedin N. RIC allogeneic stem cell transplantation for high risk Chronic Lymphocytic Leukaemia followed by pre-emptive MRD-based. 16<sup>th</sup> International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Sydney, Australia, September 2015

Letestu R, G Cartron, S Leprêtre, M Le Garff-Tavernier, F Solly, L Campos-Guyotat, M Ticchioni, A Dahmani, V Rouille, V Lévy, F Cymbalista, MH Delfau-Larue. Etude de la maladie résiduelle dans la LLC au cours de l'essai clinique de phase II randomisé FMP2010 : comparaison de la cytométrie en flux (CMF) 8 couleurs et de la PCR quantitative IGH clonospécifique. 35<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2015

Roos-Weil D, P Feugier, S Lepretre, C Lesty, S Chevret, M Diop, R Delepine, R Guièze, V Ribrag, S Raynaud, X Troussard, N Droin, O Bernard, F Nguyen-Khac. Analyse moléculaire par séquençage à haut débit ciblé d'une cohorte prospective de patients LLC inclus dans le protocole FMP2007. Journées du FILO, 2015

Roos-Weil D, Nguyen-Khac F, Chevret S, Ysebaert L, Roux C, Touzeau C, A Cosson, Cymbalista F, Feugier P, Leprêtre S, MC Béné MC, S Struski S, H Merle-Béral H, Raynaud S, Sutton L, Davi F, Leblond V. Etude moléculaire et cytogénétique d'une cohorte rétrospective de 188 patients LLC avec trisomie 12. Journées du FILO, 2015

## 2014

### Posters

Nguyen Them L., Costopoulos M, Tanguy ML, Houillier C, Choquet S, Benanni H, Elias R, Armand M, Faivre G, Glaisner S, Malak S, Vargaftig J, Hoang-Xuan K, Touitou V, Cassoux N, Davi F, Merle-Béral H, Le Garff-Tavernier M, Soussain C. IL10 and IL10:IL6 Ratio in CSF is useful at diagnosis but also in the assessment of therapeutic response in patients with primary central nervous system lymphoma (PCNSL). 56<sup>th</sup> American Society of Hematology (ASH) Congress, San Francisco, USA, December 2014

Costopoulos M, Touitou V, Golmard JL, Bonnemye S, Darugar A, Lelez ML, Soussain C, Cassoux N, Lamy T, Rabut T, Le Hoang P, Bodaghi B, Merle-Béral H, Le Garff-Tavernier M. ISOLD : a valuable score to discriminate ocular lymphoma from inflammatory diseases. 19<sup>th</sup> European Hematology Association (EHA) congress, Milan, Italy, June 2014

Belleville T, Costopoulos M, Settegrana C, Maloum K, Azgui Z, Brissard M, Bonnemye P, Choquet S, Hoang-Xuan K, Leblond V, Merle-Béral H, Le Garff-Tavernier M. Comparaison de la cytologie et du phénotypage par cytométrie en flux. 34<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, April, 2014

Costopoulos M, Touitou V, Golmard JL, Bonnemye P, Darugar A, Lelez ML, Soussain C, Cassoux N, Lamy T, Rabut E, Le Hoang P, Bodaghi B, Merle-Béral H, Le Garff-Tavernier M. ISOLD, un nouveau score cytokinique comme aide au diagnostic des lymphomes intra-oculaires. 34<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, April, 2014

### Oral communications

Wagner-Ballon O, Le Garff-Tavernier M, Observatoire des Clones HPN. 18<sup>th</sup> Association Française de Cytométrie (AFC) Congress, Lille, France, November 2014.

Djavaheri-Mergny M. Autophagy, cell death and differentiation in cancer cells. 4<sup>th</sup> international symposium on molecular technology (drug development and therapeutics) A satellite meeting of the International Cell Death Society, Tehran IRAN, October 14-16, 2014.

Djavaheri-Mergny M. Autophagy, cell death and differentiation in cancer cells". Autophagy and Cancer International Symposium Toulouse, September 15<sup>th</sup> 2014.

Le Garff-Tavernier M. Place de la Maladie Résiduelle (MRD) dans la LLC. 14<sup>èmes</sup> Journées Marocaines de Biologie Clinique, Rabat, Maroc, June 2014

Nguyen-Khac, F Damm, E Mylonas, A Cosson, V Della Valle, E Mouly, M Diop, L Scourzic, F Davi, J Lambert, D Gautheret, H Merle-Béral, L Sutton, P Dessen, E Solary, W Vainchenker, T Mercher, N Droin, O A. Bernard. Mutations acquises dans les progéniteurs hématopoïétiques de la leucémie lymphoïde chronique (LLC). Congrès de la Société Française d'Hématologie, Paris 2014.

## 2013

### Posters

Le Garff-Tavernier M, Veronese L, Nguyen-Khac F, Dilhuydy MS, Combes P, Leblond V, Feugier P, Mahé B, Sanhès L., Delmer A, Ysebaert L, Grelier A, Truchan-Graczyk M, Dreyfus B, Leprêtre S, Davi F, Pereira B, Delepine R, Guièze R, Bay JO, Merle-Béral H, De Guibert S, Tournilhac O, on Behalf of the French CLL intergroup (GCFLLC/MW - GOELAMS). p53 functional assessment and correlation with 17p deletion and/or TP53 mutation status in Chronic Lymphocytic Leukemia (CLL). A preliminary report of the ICLL001 BOMP trial. 55<sup>th</sup> American Society of Hematology (ASH) Congress, Nouvelle-Orléans, USA, December 2013

Nguyen-Khac F, A Cosson, E Chapiro, N Belhouachi, HA Cung, B Keren, F Damm, C Algrin, C Lefebvre, S fert-Ferrer, I Luquet, N Gachard, F Mugneret, C Terré, MA Collonge-Rame, L Michaux, I Radford-Weiss, P Talmant, L Veronese, N Nadal, S Struski, C Barin, C Helias, M Lafage, É Lippert, N Auger, V Eclache, C Settegrana, K Maloum, C Lesty, F Davi, H Merle-Béral. NOTCH1 Mutations Are Associated With The 14q Deletion In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). 55<sup>th</sup> Congress of American Society of Hematology, USA, December 2013

Grelier A, Le Garff-Tavernier M, Nauwelaers F, Sarfati M, Merle-Béral H. Dosage du CD23 soluble par cytométrie en flux (technique CBA) : une méthode de quantification pratique et fiable dans la Leucémie Lymphoïde Chronique. 17<sup>th</sup> Association Française de Cytométrie (AFC) Congress, Strasbourg, France, October 2013

Le Garff-Tavernier M, Veronese L, Nguyen-Khac F, Dilhuydy MS, Combes P, Leblond V, Feugier P, Mahé B., Sanhès L, Delmer A, Ysebaert L, Truchan-Graczyk M, Dreyfus B, Leprêtre S, Davi F, Pereira B, Delepine R, Guièze R, Merle-Béral H, De Guibert S, Tournilhac O, on Behalf of the French CLL intergroup (GCFLLC/MW - GOELAMS) p53 functional assessment and correlation with 17p deletion and/or TP53 mutation status. A preliminary report of the ICLL001 BOMP trial. 15<sup>th</sup> International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Stockholm, September 2013

Nguyen-Khac F, A Cosson, E Chapiro, N Belhouachi, H-A Cung, B Keren, F Damm, C Algrin, C Lefebvre, S Fert-Ferrer, I Luquet, N Gachard, F Mugneret, C Terre, M-A Collonge-Rame, L Michaux, I Radford-Weiss, P Talmant, L Veronese, N Nadal, S Struski, C Barin, C Helias, M Lafage, E Lippert, N Auger, V Eclache, C Settegrana, K Maloum, C Lesty, F Davi, H Merle-Béral. NOTCH1 mutations are associated with the 14q deletion in chronic lymphocytic leukemia and lymphocytic lymphoma. 17<sup>th</sup> Congress of European Haematology Association, Stockholm, 2013 (abstract 086)

Costopoulos M, Raimbault A, Roos-Weil D, Maloum K, Grenier A, Settegrana C, Azgui Z, Brissard M, Gueguen S, Leblond V, Merle-Béral H, Le Garff-Tavernier M. Apport du phénotypage par cytométrie en flux pour la détection des cellules lymphomateuses dans le LCR prélevé sur Transfix. 33<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2013

### Oral communications

Cosson A, Caroline Algrin, Elise Chapiro, Hong-Anh Cung, Boris Keren, Frédéric Damm, Frédéric Davi, Hélène Merle-Béral, Claude Lesty, Laurent Sutton, Santos A Susin, Florence Nguyen-Khac. Analyse structurale et fonctionnelle du gain du bras court du chromosome 2 dans la leucémie lymphoïde chronique. Congrès de la Société Française d'Hématologie, Paris 2013.

Cosson A, Frédéric Damm, Claude Lesty, Caroline Algrin, Elise Chapiro, Véronique Leblond, Frédéric Davi, Hélène Merle-Béral, Laurent Sutton, Olivier Bernard, Florence Nguyen-Khac. Analyse des nouvelles mutations

dans une cohorte de 169 LLC stades B/C non traitées, incluses dans un protocole clinique. Congrès de la Société Française d'Hématologie, Paris 2013.

Davi F, P Baliakas, E Minga, A Hadzidimitriou, A Tsanousa, L Sutton, A Agathangelidis, L Scarfo, Z Davis, J Yan 7, K Plevova, Y Sanberg, F Vojdeman, M Boudjogra, T Tzenou, M Chatzouli, C Chu, A Gardiner, L Mansouri, K Smedby, L Pedersen, D Moreno, K van Lom, V Giudicelli, B Tichy, F Nguyen-Khac, P Panagiotidis, A Anagnostopoulos, L Angelis, G Juliusson, M Lefranc, C Geisler, A Langerak, S Pospisilova, N Chiorazzi, C Belessi, D Oscier, N Darzentas, R Rosenquist, P Ghia, K Stamatopoulos. B cell receptor stereotypy makes a clinical difference in CLL: revelations from a multi-institutional series of 4615 cases. Congrès de l'European haematology association, Stockholm, Suède, 2013.

## 2012

### Posters

Cosson A, E. Chapiro, N. Belhouachi, H.A Cung, C. Algrin, F. Damm, C. Gabillaud, C. Lefebvre, S. Fert-Ferrer, I. Luquet, N. Gachard, F. Mugneret, C. Terré, M.A. Collonge-Rame, L. Michaux, I. Radford-Weiss, P. Talmant, L. Véronèse, N. Nadal, S. Struski, C. Barin, C. Helias, M. Lafage-Pochitaloff, E. Lippert, N. Auger, V. Eclache, C. Settegrana, K. Maloum, C. Lesty, H Merle-Béral, F. Davi, F. Nguyen-Khac. La mutation *NOTCH1* (p.P2515Rfs\*4) est fréquente dans les LLC/LL avec délétion du bras long du chromosome 14q. Journée LLC des jeunes experts, Paris, November 2012.

Cabon L, P Galan-Malo, A Bouharrou, L Delavallee, M-N Brunelle-Navas, HK Lorenzo, A Gross and SA Susin. BID, a key link between calpains and BAX in AIF-mediated necroptosis. 8th European Workshop on Cell Death. Monétier-les-Bains, Serre Chevalier Valley, June 2012

### Oral communications

Couronné L, C Quivoron, V delle Valle, B Arnulf, MH Stern, H Merle-Béral, F Nguyen-Khac, M Fontenay, W Vainchenker, T Mercher, C Bastard, O Bernard. Co-occurrence des mutations des gènes TET2 et DNMT3A dans les lymphomes t : vers une meilleure compréhension de la pathogenèse ? Congrès de la Société Française d'Hématologie, Paris, 2012.

Adrien Cosson, Caroline Algrin, Elise Chapiro, Hong-Anh Cung, Boris Keren, Frédéric Damm, Frédéric Davi, Hélène Merle-Béral, Claude Lesty, Laurent Sutton, Santos A Susin, Florence Nguyen-Khac. Caractérisation du gain du bras court du chromosome 2 dans la leucémie lymphoïde chronique. Journée LLC des jeunes experts, Paris, November 2012.

Bauvois B. 8<sup>ème</sup> Journée scientifique du Centre de Recherche des Cordeliers, Protéase leucocytaire CD13/aminopeptidase N, signalisation et cible potentielle thérapeutique. Paris, 8 June 2012.

Martinez-Torres AC, Susin SA. CD47-mediated caspase-independent cell death: a new therapeutic tool to overcome apoptotic avoidance in chronic lymphocytic leukemia. 8th European Workshop on Cell Death. Monétier-les-Bains, Serre Chevalier Valley, France June 2012

Piedfer M, Bouchet S, Tang R, Dauzonne D, Billard C, Bauvois B. Association between p70S6 kinase downregulation and mitochondrial dependent-cell death in acute myeloid leukemia cells. First International Congress on Cell death in Cancer, St Malo, April 13-16, 2012.

R Letestu, P Feugier, C Arnoulet, L Campos, B Chatelain, B Drenou, E Legac, M Le Garff-Tavernier, M Ticchioni, N Robillard, F Cymbalista, S Leprêtre. Intérêt de l'étude précoce de la maladie résiduelle par cytométrie en flux 6 couleurs dans le protocole CLL2007FMP de l'intergroupe GCFLLC/MW-GOELAMS. 32<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2012

S Choquet, D Leroux, C Delnatte, O Ingster, I Coupier, V Leblond, K Maloum, J Gabarre, F Nguyen Khac, M Legarff, F Davi, I Theodorou Les leucémies lymphoïdes chroniques familiales (LLCf) ont un phénotype proche des LLC de stade A sporadiques et la structure de leur famille s'oppose à celle des autres hémopathies lymphoïdes familiales (HLf). Analyse de 230 familles du registre national 32<sup>th</sup> Société Française d'Hématologie (SFH) Congress, Paris, France, March 2012

Piedfer M, Bouchet S, Tang R, Dauzonne D, Billard C, Bauvois B. A new flavone leads to apoptosis associated with p70S6kinase and phospho-Bad downregulation in leukemic acute myeloid cells. 23<sup>rd</sup> International congress on anticancer treatment, Paris, 31 january-3 february, 2012

Piedfer M, Bouchet S, Tang R, Dauzonne D, Billard C, Bauvois B. Induction de l'apoptose des cellules myéloïdes leucémiques par une flavone originale dérivée de l'acide flavonique-8-acétique. XIXèmes Journées jeunes chercheurs Chimie Thérapeutique, Bocitech, Romainville, 2-3 Février 2012

### Articles publiés dans des actes de colloques / congrès

## 2016

Mueller N, Wicklein D, Eisenwort G, Schwaab J, Jawhar M, Boehm A, Herrmann H, Stefanzl G, Hoermann G, Sperr WR, Arock M, Reiter A, Schumacher U, Valent P. Identification of CD44 As a RAS-MEK-Regulated Invasion Receptor That Is Overexpressed in Neoplastic Mast Cells and Triggers Disease Expansion in Advanced Systemic Mastocytosis. 58<sup>th</sup> American Society for Hematology (ASH). Blood 2016, 128:1955

Agathangelidis A, Hadzidimitriou A, Minga E, Sutton LA, Polychronidou E, Shanafelt TD, Davis Z, ..., Davi F, Rosenquist R, Ghia P, Stamatopoulos K. Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. 58<sup>th</sup> American Society for Hematology (ASH). Blood 2016, 128:4376

Airiau K, Micheau O, Vacher AM, Mehri F, Vacher P, Djavaheri-Mergny M. Regulation of TRAIL-induced apoptotic signaling by the autophagy receptor p62 in acute promyelocytic leukemia cells. AACR 107<sup>th</sup> Annual Meeting on Bioinformatics and Systems Biology. Cancer Research 2016, 76:3723

Roos-Weil, D, Lambert, J, Droin, NM, Damm, F, Guieze, R, Diop, M, Feugier, P, Lepretre, S, Troussard, X, Nguyen-Khac, F. Targeted Sequencing for Clinical Investigation in Chronic Lymphocytic Leukemia. 58<sup>th</sup> American Society for Hematology (ASH). Blood 2016, 128:3202

Mueller N, Wicklein D, Eisenwort G, Boehm A, Herrmann H, Stefanzl G, Hoermann G, Sperr WR, Arock M, Schumacher, U. Expression, regulation and function of the cell adhesion molecule CD44 in neoplastic mast cells and stem cells in patients with systemic mastocytosis. Oncology research and treatment 2016, 39, (Suppl 3), 24-24

Costopoulos M, Kim R, Choquet S, Maloum K, Algrin C, Houillier C, Settegrana C, Villemonteix J, Brissard M, Quiney C, Davi F, Leblond V, Merle-Beral H, Le Garff-Tavernier M. To dose or not to dose: are IL-10 and IL-10: IL-6 ratio accurate biomarkers to detect leptomeningeal involvement in small B-cell lymphoproliferations? 21<sup>st</sup> Congress of the European-Hematology-Association, Haematologica 2016, 101, (Suppl 1), 819-819

Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, Scarfo, L, Davis Z, Yan XJ, Plevova K, Sandberg Y, Vojdeman FJ, Tzenou T, Chu CC, Veroneze S, Mansouri L, Smedby KE, Giudicelli V, Nguyen-Khac F, ..., Stamatopoulos K. No improvement in long-term overall survival after the introduction of chemo(immuno)therapy for chronic lymphocytic leukemia patients belonging to stereotyped subset #2. 21<sup>st</sup> Congress of the European-Hematology-Association, Haematologica 2016, 101, (Suppl 1), 231-231

Mueller N, Wicklein D, Eisenwort G, Boehm A, Herrmann H, Stefanzl G, Hoermann G, Sperr WR, Arock M, Schumacher U. Expression, regulation, and functional role of hermes adhesion receptor CD44 in neoplastic mast cells in systemic mastocytosis. Conference: 21<sup>st</sup> Congress of the European-Hematology-Association, Haematologica 2016, 101, (Suppl 1), 190-190

Tournilhac O, Le Garff-Tavernier M, Tabrizi R, Quoc SN, Legrand-Izadifar F, Chevallier P, Reman O, ..., Merle-Beral H, Dhedin N. RIC allogeneic stem cell transplantation for high risk CLL followed by preemptive MRD-based immunointervention - intermediate results from the phase II ICLLO3 RICAC-PMM trial (GCFLLC/MW - GOELAMS - SFGMTC French intergroup) (NCT00935324). 42<sup>nd</sup> Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Bone marrow transplantation 2016, 51, (Suppl 1), S447-S448

## 2015

Roos-Weil D, Feugier P, Lepretre S, Chevret S, Diop K, Delepine R, Guièze R, Ribrag V, Raynaud S, Troussard X, Droin N, Bernard O, Nguyen-Khac F. Analyse moléculaire par séquençage à haut débit ciblé de 161 LLC non traitées incluses dans un protocole prospectif. Congrès de la Société Française d'Hématologie, Paris, Hématologie 2015, 21, (Suppl 1), 04-32.

Cosson A, E Chapiro, J Lambert, H-A Cung, C Algrin, F Damm, C Gabillaud, F Davi, H Merle-Béral, S Choquet, M Uzunov, V Morel, V Leblond, S Leprêtre, P Feugier, C Lesty, J Lejeune, L Sutton, S A. Susin, F Nguyen-Khac. Le gain du bras court du chromosome 2 (2p) entraîne une résistance aux traitements dans la Leucémie Lymphoïde Chronique (LLC). Congrès de la Société Française d'Hématologie, Paris, Hématologie 2015, 21, (Suppl 1), 04-23.

Guièze R, P Robbe, R Clifford, S De Guibert, A Timbs, MS Dilhuydy, M Cabes, L Ysebaert, A Burns, F Nguyen Khac, F Davi, L Véronèse. Spectre mutationnel de la leucémie lymphoïde chronique réfractaire ou en rechute: un profil à plusieurs événements. Congrès de la Société Française d'Hématologie, Paris. Hématologie 2015, 21, (Suppl 1), 04-31.

Cosson, A, Chapiro, E, Lambert, J, Cung, HA, Algrin, C, Damm, F, Merle-Beral, H, Susin, SA, Nguyen-Khac, F. The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia. Conference: 57<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, Orlando, Blood 2015, 126: 492

Kim R, Costopoulos M, Choquet S, Maloum K, Algrin C, Hoang-Xuan K, Settegrana C, Villemonteix J, Brissard M, Davi F, Leblond V, Merle-Beral H. To Dose or Not to Dose: Are IL-10 and IL-6 Accurate Biomarkers to Detect Leptomeningeal Involvement in Small B-Cell Lymphoproliferation? 57<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, Orlando, Blood 2015, 126: 23

Tournilhac O, Le Garff-Tavernier M, Tabrizi R, Quoc SN, ..., Legrand-Izadifar F, Merle-Beral H, Dhedin N. RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Intermediate Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO & SFGM-TC French intergroup). Conference: 57<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, Orlando, Blood 2015, 126: 23

Wanquet A, Birsen R, Choquet S, Levy V, Dupuis J, Lepretre S, Re D, Fahri J, Hunault M, ..., Davi F, ..., Aurrant-Schleinitz T. Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients . Conference: 57<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, Orlando, Blood 2015, 126: 23

Navrkalova V, Young E, Baliakas P, Radova L, Plevova K, Sutton LA, Mansouri L, Ljungstrom V, Ntoufa S, Davis Z, Juliusson G, Smedby KE, Belessi C, Panagiotidis P, Davi F, ..., Rosenquist R. ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome . Conference: 57<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, Orlando, Blood 2015, 126: 23

Armand M, Boudjoghra M, Xochelli A, Canioni D, Le Garff-Tavernier ML, Colombo M, Rabiega P, Molina T, Charlotte F, ..., Davi F. Auto-Immune Origin of B Cells from HCV-Associated Lymphoma . Conference: 57<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, Orlando, Blood 2015, 126: 23

Noerenberg D, Young E, Ljungstrom V, Mansouri L, Plevova K, Baliakas P, Blakemore S, Rossi D, Clifford R, Davi F, Damm F. EGR2 Mutations in Chronic Lymphocytic Leukemia: A New Bad Player . Conference: 57<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, Orlando, Blood 2015, 126: 23

Chatzilari E, Baliakas P, Xochelli A, Maronidis A, Vardi A, Mattsson M, Larsson K, Douka V, Iskas M, Karavalakis G, Papalexandri A, Niemann C, Montillo M, Anagnostopoulos A, Oscier D, Pospisilova S, Davi F, ..., Kompatsiaris Y. Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy? Conference: 57<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, Orlando, Blood 2015, 126: 23

Xochelli A, Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tausch E, Yan XJ, Davi F, ..., Stamatopoulos K. CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference . Conference: 57<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, Orlando, Blood 2015, 126: 23

Xochelli A, Bikos V, Polychronidou E, Agathangelidis A, Charlotte F, Moschonas P, Davis Z, Colombo M, Roumelioti M, Sutton LA, Davi F, Stamatopoulos K. Unique Versus Common: Disease-Biased Immunoglobulin Gene Repertoires Along with Public Antigen Receptor Stereotypes in Marginal Zone B-Cell Lymphoproliferations. 57<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, Orlando, Blood 2015, 126: 23

Martinez-Torres AC, Quiney C, Attout T, Boulet H, Herbi L, Vela L, Barbier S, Chateau D, Chapiro E, Nguyen-Khac F, Davi F, Le Garff-Tavernier M, Moumné R, Sarfati M, Karoyan P, Merle-Béral H, Launay P, Susin SA. CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCg1 activation: evidence from mice and humans. 20<sup>th</sup> Congress of the European-Hematology-Association, Vienna, Austria, Haematologica 2015, 100 (Suppl 1): 420

Cosson A, E Chapiro, J Lambert, H-A Cung, C Algrin, F Damm, C Gabillaud, F Davi, H Merle-Béral, S Choquet, M Uzunov, V Morel, V Leblond, S Leprêtre, P Feugier, C Lesty, J Lejeune, L Sutton, S A Susin, F Nguyen-Khac. The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia. 20<sup>th</sup> Congress of the European-Hematology-Association, Vienna, Austria, Haematologica 2015, 100 (Suppl 1), 222

Baliakas P, Puiggros A, Xochelli A, Sutton LA, Nguyen-Khac F, Gardiner A, Plevova K, Ortega M, Collado R, Gonzalez T, ..., Stamatopoulos K. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the partner chromosome makes a difference. 20<sup>th</sup> Congress of the European-Hematology-Association, Vienna, Austria, Haematologica 2015, 100 (Suppl 1), 224

Costopoulos M, Belleville T, Settegrana C, Maloum K, Azgui, Z, Brissard M, Merle-Beral H, Le Garff-Tavernier M. Flow cytometry immunophenotyping and cytological analyses of csf: a comparison of performances for lymphomatous cell detection . Conference: 20<sup>th</sup> Congress of the European-Hematology-Association, Vienna, Austria, Haematologica 2015, 100 (Suppl 1), 554

Ljungstrom V, Cortese D, Young E, Pandzic T, Mansouri L, Plevova K, Sutton LA, Stavroyianni N, Davi F, Rosenquist R. Dissecting resistance mechanisms in chronic lymphocytic leukemia using whole-exome sequencing: impact of recurrent rps15 mutations on p53 dysregulation . 20<sup>th</sup> Congress of the European-Hematology-Association, Vienna, Austria, Haematologica 2015, 100 (Suppl 1), 10-11

Agathangelidis A, Bystry V, Hadzidimitriou A, Sutton LA, Minga E, Kienle D, Davis Z, Yan XJ, Davi F, Stamatopoulos K. Higher-order immunoglobulin sequence relations for major subsets of chronic lymphocytic leukemia: uniqueness versus equivalence. 20<sup>th</sup> Congress of the European-Hematology-Association, Vienna, Austria, Haematologica 2015, 100 (Suppl 1), 47-48

Wanquet A, Birsén R, Choquet S, Levy V, Dupuis J, Lepretre S, Re D, Fahri J, Hunault M, Davi F, Aurran-Schleinitz T. Management of central nervous system involvement in chronic lymphocytic leukemia: a retrospective cohort of 30 patients. Leukemia & Lymphoma 2015, 56 (Suppl 1), 140-141

Tournilhac O, Tabrizi R, Le Garff-Tavernier M, Quoc N, Legrand-Izadifar F, Chevallier P, Coudert M, Merle-Beral H, Dhedin N. RIC allogeneic stem cell transplantation for high risk CLL followed by preemptive MRD-based immunointervention - intermediate results from the phase II ICLL03 RICAC-PMM trial (FILO-SFGM. TC French intergroup). Leukemia & Lymphoma 2015, 56 (Suppl 1), 162-163

Young E, Norenberg D, Ljungstrom V, Mansouri L, Plevova K, Baliakas P, Rossi D, Navrkalova V, Sutton LA, Davi F, Damm F. EGR2 mutations in chronic lymphocytic leukemia- a new bad player? Leukemia & Lymphoma 2015, 56 (Suppl 1), 83-85

Michallet AS, Andrieu T, Mondiere P, Servanton H, Davi F, Dussurgey S, Defrance T. Analysis of the tumor imprint on the residual normal B cell compartment of CLL patients by mass cytometry. Leukemia & Lymphoma 2015, 56 (Suppl 1), 8

Espinet Sola, BE, Baliakas, P, Puiggros, A, Xochelli, A, Sutton, LA, Nguyen-Khac, F, Gardiner, A, Plevova, K, Ortega, M, Davi F, Stamatopoulos, K. Clinical- biological characterization of the patients with llc and trisomy 12 that exhibit additional trisomies: importance of the accompanying alterations. 57<sup>th</sup> National Congress of the Spanish-Society-of-Hematology-and-Hemotherapy, Valencia, Spain, Haematologica 2015, 100 (Suppl 4), 67

## 2014

Nguyen-Khac F, F Damm, E Mylonas, A Cosson, V Della Valle, E Mouly, M Diop, L Scourzic, F Davi, J Lambert, D Gautheret, H Merle-Béral, L Sutton, P Dessen, E Solary, W Vainchenker, T Mercher, N Droin, O A. Bernard. Mutations acquises dans les progéniteurs hématopoïétiques de la leucémie lymphoïde chronique (LLC). Congrès de la Société Française d'Hématologie, Paris 2014. Hématologie, 22, (Suppl 3), 02-07.

Xochelli, A, Agathangelidis, A, Kavakiotis, I, Minga, E, Sutton, LA, Baliakas, P, Chouvarda, I, Giudicelli, V, Davi F, Stamatopoulos, K. Immunoglobulin heavy variable genes and alleles: new entities, new names and implications for research and prognostication in CLL. 19<sup>th</sup> Congress of the European-Hematology-Association, Milan, Italie. Haematologica 2014, 99 (Suppl 1), 49

Sutton, LA, Young, E, Baliakas, P, Hadzidimitriou, A, Plevova, K, Rossi, D, Malcikova, J, Stalika, E, Davi, F, Stamatopoulos, K, Rosenquist, R. Subset-Specific Spectra of Recurrent Gene Mutations in Chronic Lymphocytic Leukemia with Stereotyped B-Cell Receptors. 19<sup>th</sup> Congress of the European-Hematology-Association, Milan, Italie. Haematologica 2014, 99 (Suppl 1), 49

Damm, F, Mylonas, E, Cosson A, Merle-Beral H, Sutton, L, Dessen, P, Solary, E, Akashi, K, Vainchenker, W, Nguyen-Khac F, Bernard, OA. Acquired initiating mutations in early hematopoietic cells of chronic lymphocytic leukemia patients. 19<sup>th</sup> Congress of the European-Hematology-Association, Milan, Italie. Haematologica 2014, 99 (Suppl 1), 227

Costopoulos, M, Touitou, V, Golmard, JL, Bonnemye, P, Darugar, A, Lelez, ML, Soussain, C, ..., Merle-Beral, H, Le Garff-Tavernier, M. Isold: a valuable score to discriminate ocular lymphoma from inflammatory diseases. 19<sup>th</sup> Congress of the European-Hematology-Association, Milan, Italie. Haematologica 2014, 99 (Suppl 1), 408-408

Maloum, K, Settegrana, C, Chapiro, E, Le Garff-Tavernier, M, Cosson, A, Leblond, V, Davi, F, Merle-Beral, H, Nguyen-Khac, F. B cell lymphoproliferative disorders with circulating tetraploid cells : from cytology to cytogenetic. 19<sup>th</sup> Congress of the European-Hematology-Association, Milan, Italie. Haematologica 2014, 99 (Suppl 1), 583-584

Sellner, L, Oles, M, Anders, S, Zapatka, M, Lukas, M, Slabicki, M, Blume, C, Hullein, J, Stolz, T, Muley, C, Nguyen-Khac F, Zenz, T. Systematic drug sensitivity screening in lymphoid malignancies identifies vulnerabilities of chronic lymphocytic leukemia with high risk aberrations. 19<sup>th</sup> Congress of the European-Hematology-Association, Milan, Italie. Haematologica 2014, 99 (Suppl 1), 316

de Guibert, S, Dilhyudy, MS, Ysebaert, L, Sanhes, L, Choquet, S, Aurran-Schleinitz, T, Guieze, R, Le Garff-Tavernier M, Nguyen-Khac F, Tournilhac, O. Salvage treatment with bendamustine, ofatumumab, high-dose methylprednisolone (bomp) in high-risk r/r cl: interim results of the french cl intergroup (gcflc/mw - goelams) ICLL01 phase 2 trial. 19<sup>th</sup> Congress of the European-Hematology-Association, Milan, Italie. Haematologica 2014, 99 (Suppl 1), 60-61

Baliakas, P, Hadzidimitriou, A, Sutton, LA, Minga, E, Agathangelidis, A, Tsanousa, A, Scarfo, L, Davis, Z, ..., Nguyen-Khac, F, ..., Davi, F, ..., Stamatopoulos, K. Not all ighv3-21 cll are equal: subset #2 displays a distinctive clinicobiological profile with remarkable similarities to subset #169, its close immunogenetic relative. 19<sup>th</sup> Congress of the European-Hematology-Association, Milan, Italie. Haematologica 2014, 99 (Suppl 1), 48-49

Darzentas, N, Davi, F, Ghia, P, Rosenquist, R, Hadzidimitriou, A, Belessi, C, Lefranc, MP, Stamatopoulos, K. Immunoglobulin heavy variable genes and alleles: new entities, new names and implications for research and prognostication in CLL. 19<sup>th</sup> Congress of the European-Hematology-Association, Milan, Italie. Haematologica 2014, 99 (Suppl 1), 49

Sutton, LA, Ljungstrom, V, Mansouri, L, Young, E, Cortese, D, Navrkalova, V, Malcikova, J, Muggen, AF, Trbusek, M, Davi F, Rosenquist, R. TAP63 is epigenetically regulated and highly overexpressed in aggressive cll stereotyped subset #8. 19<sup>th</sup> Congress of the European-Hematology-Association, Milan, Italie. Haematologica 2014, 99 (Suppl 1), 313

Sutton, LA, Ljungstrom, V, Mansouri, L, Young, E, Cortese, D, Navrkalova, V, Malcikova, J, Muggen, AF, Trbusek, M, Davi F, Rosenquist, R. Targeted next-generation sequencing for mutational screening in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation within a clinical setting. 19<sup>th</sup> Congress of the European-Hematology-Association, Milan, Italie. Haematologica 2014, 99 (Suppl 1), 313-314

Wedeh G, Cerny-Reiterer S, Hadzijušufovic E, Herrmann H, Blatt K, Eisenwort G, Hoermann G, Sperr WR, Muellauer L, Vakoc CR, Bradner JE, Horny H, Zuber J, Arock M, Valent P. The epigenetic reader brd4 serves as a novel marker and target in aggressive systemic mastocytosis and mast cell leukemia. 19<sup>th</sup> Congress of the European-Hematology-Association, Milan, Italie. Haematologica 2014, 99 (Suppl 1), 514-515

Letestu R, Cartron G, Lepretre S, Le Garff-Tavernier M, Solly F, Campos L, Ticchioni M, Quiney C, Dahmani A, Boubaya M, Levy V, Cymbalista, F, Delfau-Larue, MH. Minimal Residual Disease (MRD) By 8-Color Flow Cytometry (Flow-MRD) and IGH Clonospesific Quantitative PCR (ASO RQPCR) Reached Similar Performances for Evaluation of CLL Treatment in a Phase II Clinical Trial: Cross Validation of the Methods. 56<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, San Francisco, CA. Blood 2014, 124 Issue: 21

de Guibert, S, Dilhuydy, MS, Ysebaert, L, Sanhes, L, Choquet, S, Aurran-Schleinitz, T, Le Garff-Tavernier, M, Lauren, V, Schuh, A, Pereira, B, Leblond, V, Tournilhac, O. Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial. Conference: 56<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, San Francisco, CA. Blood 2014, 124 Issue: 21

Xochelli, A, Kavakiotis, I, Agathangelidis, A, Kienle, D, Davis, Z, Yan, XJ, Shanafelt, T, Boudjogra, M, Plevova, K, Chatzouli, M, Pedersen, LB, Davi F, Stamatopoulos, K. Charting Unique Signatures of Somatic Hypermutation Amongst Chronic Lymphocytic Leukemia Patients Expressing IGHV4-34 Clonotypic B Cell Receptors. 56<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, San Francisco, CA. Blood 2014, 124 Issue: 21

Baliakas, P, Hadzidimitriou, A, Sutton, LA, Minga, E, Agathangelidis, A, Tsanousa, A, Scarfo, L, Davis, Z, Nguyen-Khac F, Davi F, Rosenquist, R, Ghia, P, Stamatopoulos, K. Clinical Impact of Stereotyped Antigen Receptors in Chronic Lymphocytic Leukemia Group Author(s): ERIC. 56<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, San Francisco, CA. Blood 2014, 124 Issue: 21

Baron M, Gyan E, Merle-Beral H, Leblond V, Cassoux N, Touitou V, Bodaghi B, Darugar A, Choquet S. High Efficiency and Tolerance of Temozolomide in Relapse/Refractory Primary Intra-Ocular Lymphoma (R/R PIOL). a Retrospective Multicentric Study from the LOC Network. 56<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, San Francisco, CA. Blood 2014, 124 Issue: 21

Farren TW, Liu FT, Le Garff-Tavernier M, Sarfati, M, Nauwelaers F, Keenan J, Warner, N, Merle-Beral H, Agrawal SG. Soluble CD23 (sCD23): A Forgotten Indicator of Prognosis and Identifier of Outcome in Patients with Chronic Lymphocytic Leukemia Utilizing a Novel Cba Approach. 56<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, San Francisco, CA. Blood 2014, 124 Issue: 21

Robbe P, Guieze R, Clifford RM, ..., Nguyen-Khac F, Davi F, Veronese L, Combes P, Le Garff-Tavernier M, Leblond V, Merle-Beral H, ..., Tournilhac O. Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing. 56<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, San Francisco, CA. Blood 2014, 124 Issue: 21

Nocturne G, Boudaoud S, Besson C, Davi F, Canioni D, Cacoub P, Hermine O, Mariette X. Genetic Variants of TNFAIP3 in Patients with HCV Related Lymphoma Are Associated with the Presence of Rheumatoid Factor (RF). 56<sup>th</sup> Annual Meeting of the American-Society-of-Hematology San Francisco, CA. Blood 2014, 124, Issue 21



Mansouri L, Sutton LA, Ljungstrom V, Bondza S, Arngarden L, Bhoi S, Larsson J, Cortese D, Davi F, Rosenquist R. Recurrent Mutations within the Nfkbie gene: A Novel Mechanism for NF-kappa B Deregulation in Aggressive Chronic Lymphocytic Leukemia. 56<sup>th</sup> Annual Meeting of the American-Society-of-Hematology San Francisco, CA. Blood 2014, 124, Issue 21

Wedeh G, Cerny-Reiterer S, Hadzizusufovic E, Eisenwort G, Herrmann H, Blatt K, Muellauer L, Schwaab J, Bradner JE, Sperr WR, Reiter A, Horny HP, Willmann M, Zuber J, Arock M, Valent P. Bromodomain-containing protein 4 (BRD4): a novel therapeutic target in advanced mast cell neoplasms. Oncology Research and Treatment 2014, 37 (Suppl 5), 198-199

Nocturne G, Boudaoud S, Besson C, Davi F, Canioni D, Cacoub P, Hermine O, Mariette X. Genetic Variants of TNFAIP3 in Patients with HCV Related Lymphoma Are Associated with the Presence of Rheumatoid Factor (RF). Arthritis & Rheumatology 2014 (Suppl 10), S945-S945

## 2013

Roos-Weil D, F Nguyen-Khac, S Chevret, C Roux, C Touzeau, A Cosson, F Cymbalista, P Feugier, S Leprêtre, M-C Bene, S Raynaud, L Sutton, F Davi and V Leblond. Mutational and Cytogenetic Analyses Of 177 CLL Patients With Trisomy 12: A Retrospective Study Of The CLL French Intergroup. 55<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, New Orleans, LA. Blood 2013 122:4144

Ferreira P, Villanueva R, Uson A, Miramar MD, Susin SA, Peleato ML, Medina M. Unraveling the rôle of the réductase activity of the human Apoptosis-Inducing Factor. Flavins and Flavoproteins 2011 (17th International Symposium on Flavins and Flavoproteins), pp 35-66. Eds. S. Miller, R. Hille, B. Palfey. ISBN: 9781300786405.

Nguyen-Khac F, Adrien Cosson, Elise Chapiro, Nabila Belhouachi, hong-Anh Cung, Boris Keren, Frederik Damm, Caroline Algrin, Christine Lefebvre, Sandra fert-Ferrer, ..., Frederic Davi, Hélène Merle-Beral. NOTCH1 Mutations Are Associated With The 14q Deletion In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). 55<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, New Orleans, LA. Blood 2013 122:2561

Canioni, D, Michot, JM, Settegrana, C, Driss, H, Rabiéga, P, ..., NGuuyen-Khac, F, Merle-Beral, H, Taoufik, Y, Carrat, F, Davi, F, Hermine, O, Besson, C. Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients. 55<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, New Orleans, LA. Blood 2013, 122: 3005

Nguyen-Khac, F, Cosson, A, Chapiro, E, Belhouachi, N, Cung, HA, Gachard, N, Mugneret, F Terre, C, ..., Davi, F, Merle-Beral, H. NOTCH1 Mutations Are Associated With The 14q Deletion In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) 55<sup>th</sup> Annual Meeting of the American-Society-of-Hematology, New Orleans, LA. Blood 2013, 122: 2561

Cosson A, Caroline Algrin, Elise Chapiro, Hong-Anh Cung, Boris Keren, Frédéric Damm, Frédéric Davi, Hélène Merle-Béral, Claude Lesty, Laurent Sutton, Santos S Susin, Florence Nguyen-Khac. Analyse structurelle et fonctionnelle du gain du bras court du chromosome 2 dans la leucémie lymphoïde chronique. Congrès de la Société Française d'Hématologie, Paris 2013. Hématologie, 19, (suppl 2), 04-15.

Cosson A, Frédéric Damm, Claude Lesty, Caroline Algrin, Elise Chapiro, Véronique Leblond, Frédéric Davi, Hélène Merle-Béral, Laurent Sutton, Olivier Bernard, Florence Nguyen-Khac. Analyse des nouvelles mutations dans une cohorte de 169 LLC stades B/C non traitées, incluses dans un protocole clinique. Congrès de la Société Française d'Hématologie, Paris 2013. Hématologie, 19, (suppl 2), 04-17.

Baliakas P, E Minga, A Hadzidimitriou, A Tsanousa, L Sutton, A Agathangelidis, L Scarfo, Z Davis, ..., F Nguyen-Khac, ..., K Stamatopoulos. B cell receptor stereotypy makes a clinical difference in clt: revelations from a multi-institutional series of 4615 cases. Congrès de l'European haematology association, Stockholm, Suède, 2013, Haematologica, 98 (suppl 1), p218.

## 2012

Van VQ, Baba N, Wakahara K, Rubio M, Pancini B, Richard C, Soucy G, Franchimont D, Fortin G, Martinez-Torres AC, Cabon L, Susin SA, and Sarfati M. CD47Low status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice. 99th Annual Meeting of the American-Association-of-Immunologists, Boston, USA, J Immunol 2012, 188

Choquet, S, Weil, DR, Xuan, KH, Cassoux, N, Merle-Beral, H, Leblond, V. High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory Primary Central-Nervous System and Intra-Ocular Non Hodgkin Lymphoma, After First Line Treatment Containing High Doses of Methotrexate and Cytarabine. A Monocentric Retrospective Study From 2010 to 2012 on 17 Cases. 54<sup>th</sup> Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA. Blood 2012, 120, Issue: 21, Meeting Abstract: 3664

Le Garff-Tavernier M, Herbi L, de Romeuf, C, Prost, JF, Debre, P, Urbain, R, Leblond, V, Vieillard, V, Merle-Beral H. 54<sup>th</sup> Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA. Blood 2012, 120, Issue: 21,1654

te Raa, D, Malcikova, J, Mraz, M, Pospisilova, S, Le Garff-Tavernier, M, Merle-Beral, H, Stankovic, T, van Oers, MHJ, Eldering, E, Stilgenbauer, S, Zenz, T, Kater, AP. Assessment of p53 Functionality in Chronic Lymphocytic Leukemia by Different Assays; An Eric-Wide Approach. 54<sup>th</sup> Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA. Blood 2012, 120, Issue: 21, 2872

Dartigeas, C, Van Den Neste, E, Berthou, C, Maisonneuve, H, Lepretre, S, Dilhuydy, MS, Bene, MC; Nguyen-Khac, F, Leblond, V. Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) Aged > 65 years : Results of a Multicenter Trial (LLC 2007 SA) On Behalf of the French Goelams/Fcgcll-WM Intergroup. Conference: 54<sup>th</sup> Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA. Blood 2012, 120, Issue: 21, 434

Neven, B, Mamessier, E, Bruneau, J, Kaltenbach, S, Suarez, F, Doz, F, Orbach, D, Minard, V, Frange, P, Canioni, D, Radford-Weiss, I, Asnafi, V, Casanova, JL, Blanche, S, Picard, C, Rieux-Laucat, F, Davi, Fischer, A. A Mendelian Predisposition to B Cell Lymphoma Caused by IL-10R2 Deficiency . 54<sup>th</sup> Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA. Blood 2012, 120, Issue: 21, 5092

Xochelli, A, Marantidou, F, Stalika, E, Sutton, LA, Navarro, A, Supikova, J, Karypidis, K, Chatzouli, M, ..., Davi F, Stamatopoulos, K . High Expression of Activation-Induced Cytidine Deaminase and in Vivo Class Switch Recombination in Mantle Cell Lymphoma: Further Support for Antigen Involvement in Lymphomagenesis. 54<sup>th</sup> Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA. Blood 2012, 120, Issue: 21,1538

Guy, J, Antony-Debre, I, Arnoux, I, Fossat, C, Benayoun, E, Le Garff-Tavernier M, Raimbault, A, Imbert, M, Maynadie, M, Lacombe, F, Bene, MC, Wagner-Ballon, O. Conference: 54<sup>th</sup> Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA. Blood 2012, 120, Issue: 21, 1450

Loosen, C, Debliquis, A, Le Garff-Tavernier M, Letestu, R, Fossat, C, Drenou, B, Chatelain, B. Use of principal component analysis in a franco-belgian workshop on pnh diagnosis by flow cytometry . Conference: 12th Euroconference on Clinical Cell Analysis in conjunction with its 8<sup>th</sup> European Clinical Cytometry Course, Budapest, Hungary. Cytometry part B-Clinical Cytometry 2012, 82B, Issue: 6, 388

### Autres produits présentés dans des colloques / congrès et des séminaires de recherche

#### 2017

Costopoulos M. Comparaison de la biologie moléculaire et de la cytométrie en flux pour la mise en évidence d'une dissémination méningée lymphomateuse. Annual meeting of the French LOC (Lymphome Oculo-Cérébraux) network, January 2017 (Oral communication)

Djavaheri-Mergny M. Autophagy in cancer and cancer therapy, 4 Avril 2017, Séminaire BCGD (Biologie cellulaire gathering Bordeaux), Bordeaux.

Susin SA. AIF loss deregulates hematopoiesis and reveals the adaptive metabolic responses of bone marrow cells and thymocytes. April 2017. Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias. U. Zaragoza, Spain (seminar)

Djavaheri-Mergny M. Cell death and Differentiation in cancer cells. 8 Mars 2017, UMR INSERM U1085, Rennes (seminar)

Djavaheri-Mergny M. Cell death and Differentiation in Leukemia cells. 15 Février 2017, UMRS 1138 Paris (seminar)

Djavaheri-Mergny M. Autophagy, Cell death and Differentiation in Leukemia cells. 6 Février 2017, INSERM U1016 Paris (seminar)

Le Garff-Tavernier M. Projet d'étude rétrospective nationale sur l'IL-10 dans le LCR. Apport du réseau LOC pour la définition du seuil diagnostique de l'IL-10 dans les lymphomes cérébraux et /ou oculo-cérébraux primitifs (PCNSL). Annual meeting of the French LOC (Lymphome Oculo-Cérébraux) network, January 2017. (Oral communication)

Chapiro E. Impact pronostique des diverses anomalies chromosomiques entraînant la délétion 17p dans la leucémie lymphoïde chronique. Une étude du GFCH. Congress of the Société Française d'Hématologie, Paris, March 2017 (Oral Communication)

**2016**

Djavaheri-Mergny M. Autophagy, Cell death and Differentiation in Leukemia cells. 5 Décembre 2016, INSERM UMR-S 1007, Paris (seminar)

Susin SA. Role of AIF in OXPHOS regulation. November 2016. Novartis Institute for Medical research, Basel, Switzerland (seminar)

Susin SA. Mitochondrial OXPHOS and hematopoiesis. November 2016. U. Paris V (seminar)

Costopoulos M. Place du dosage des cytokines IL-10 et IL-6 pour la détection des atteintes méningées des lymphoproliférations B à petites cellules. « Journées Et Demain ! », Marseille, France, September 2016 (Oral communication)

Magali Le Garff-Tavernier. Anomalies de p53 dans la LLC : États des lieux et apport du test fonctionnel par CMF GEIL day (Groupe d'Etude Immunologiques des Leucémies), Paris, France, June 2016 (Oral communication)

Nguyen-Khac F. Apport de la cytogénétique dans les myélodysplasies. 3<sup>e</sup> congrès international francophone de biologie clinique et médecine de laboratoire, Rabat, Morocco, September 2016 (seminar)

**2015**

Magali Le Garff-Tavernier. To Dose or Not to Dose ? Est-ce-que l'IL-10 et l'IL-6 sont des biomarqueurs d'intérêt pour la détection des localisations méningées des lymphoproliférations B systémiques à petites cellules? Annual meeting of the French LOC (Lymphome Oculo-Cérébraux) network, December 2015 (Oral communication)

Nguyen-Khac F. Cytogenetics in CLL. Echanges avec le Brésil, Paris, France. September 2015 (seminar)

Susin SA. El suicidio celular: la muerte necesaria para la vida. Academia de medicina. June 2015. Zaragoza, Spain (seminar)

Susin SA. Caspase-independent cell death: a new means to modulate cell death in chronic lymphocytic leukemia. U. Murcia, Spain. April 2015. (seminar)

Nguyen-Khac F. Difficultés d'interprétation de l'hybridation *in situ* fluorescente (FISH) sur coupes anatomopathologiques, ONCOMOLPATH, Réunion Technique, Paris. March 2015

Susin SA. CD47-mediated cell death : a new therapeutic approach against chronic lymphocytic leukemia ? Centre de Recherche du Hospitalier de l'Université de Montréal, Canada. March 2015. (seminar)

Chapiro E. Caractérisation cytogénétique et moléculaire des leucémies prolymphocytaires B. Une étude du GFCH. Congress of the Société Française d'Hématologie, Paris, March 2015 (Oral Communication)

**2014**

Costopoulos M. ISOLD, un nouveau score cytokinique pour le diagnostic des lymphomes intra-oculaires. GFHC day (Groupe francophone d'Hématologie Cellulaire); Paris, France, November 2014 (Oral communication)

Belleville T, Costopoulos M. Comparaison de la cytologie et du phénotypage par cytométrie en flux. GFHC day (Groupe francophone d'Hématologie Cellulaire) ; Paris, France, November 2014 (Oral communication)

Susin SA. Implication d'AIF dans la mort cellulaire et la physiologie mitochondriale : exemples de la nécroptose intrinsèque et l'hématopoïèse. UMR INSERM U1085, Rennes, France. October 2014 (seminar)

Le Garff-Tavernier M. Assessment of Minimal Residual Disease (MRD) and of P53 evaluation pathway by flow cytometry. PRECEPTORSHIP BRESIL organized by the French Cooperative Group on CLL and WM, Paris, France, September 2014 (Oral communication)

Nguyen-Khac F. Cytogenetic abnormalities in CLL. Echanges avec le Brésil sur la LLC, Paris, September 2014 (seminar)

Nguyen-Khac F. Anomalies cytogénétiques dans la LLC. 2<sup>e</sup> congrès international francophone de biologie clinique et médecine de laboratoire, Rabat, Morocco, September 2014 (seminar)

Le Garff-Tavernier M. Actualisation des données cytokiniques pour le diagnostic des lymphomes oculaires GEIL day (Groupe d'Etude Immunologiques des Leucémies), Paris, France, June 2014 (Oral communication)

Susin SA. AIF-mediated programmed necrosis: a highly regulated way to die. ULB-Campus Erasmus. Brussels, Belgium, March 2014 (seminar)

**2013**

Costopoulos M. Actualisation des données cytokiniques pour le diagnostic des lymphomes oculaires. Annual meeting of the French LOC (Lymphome Oculo-Cérébraux) network, Paris, France, December 2013 (Oral communication)

Susin SA. Caspase-independent cell death: a new means to modulate cell death in chronic lymphocytic leukemia. Universidad Autónoma de Nuevo León, Mexico. November 2013. (seminar)

Arock M.: Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms. 55<sup>th</sup> American Society for Hematology (ASH), October 2013 (Oral communication)

Arock M. Imatinib Inhibits SCF-Induced Development Of Human Mast Cells *In Vitro* and Induces Profound and Selective Mast Cell Deficiency In Patients With Ph+ CML. 55<sup>th</sup> American Society for Hematology (ASH), October 2013 (Oral communication)

Arock M. Consensus response criteria in advanced systemic mastocytosis. *Blood* 2013 121:2393-2401. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM,. June, 2013 (Oral communication)

Djavaheri-Mergny M. Régulation de l'autophagie au cours de la différenciation des cellules leucémiques, Toulouse CRCT-INSERM U1037. June 2013 (seminar)

Nguyen-Khac F. LLC et délétion 14q. Séance d'actualité en cytogénétique. Congrès de la Société Française d'Hématologie, Paris, France, May 2013 (seminar)

Susin SA. AIF-mediated programmed necrosis: a highly regulated way to die. Queen's Cancer Research Institute, Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada. February 2013 (seminar)

Nguyen-Khac F. Anomalies cytogénétiques dans la LLC. Laboratoire pharmaceutique Amgen, Centre d'Ecologie Cellulaire, Pitié-Salpêtrière, Paris, France, January 2013 (seminar)

**2012**

Susin SA. AIF-mediated programmed necrosis: a highly regulated way to die. Département Intégrité du génôme CNRS-UMR 7175, Ecole Supérieure de Biotechnologie de Strasbourg, Illkirch, October 2012 (seminar)

Djavaheri-Mergny M. Rôle de l'autophagie dans le contrôle de la mort et la différenciation des cellules cancéreuses. Laboratoire «NeoVasc», Région-Inserm Team - ERI28, Rouen, June 2012 (seminar)

Susin SA. BID, a key link between calpains and BAX in AIF-mediated necroptosis. *Weizmann Institute of Science*, Rehovot, Israel, May 2012 (seminar)

Susin SA. Sequential activation of poly(ADP-ribose) polymerase 1, calpains, and Bax is essential in apoptosis-inducing factor-mediated programmed necrosis. Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès) Barcelona, April 2012 (seminar)

Bauvois B. Protéases leucocytaires, signalisation et cibles potentielles thérapeutiques. Inserm UMRS945, Hôpital La Pitié-Salpêtrière, Paris. Mars 2012 (seminar)

Susin SA. Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Madrid, Spain, January 2012 (seminar)

Nguyen-Khac F. QMP5F et hémopathies. Congrès de la Société Française d'Hématologie, Paris, France, March 2012 (seminar)

Nguyen-Khac F. Signification clinique de la perte d'un chromosome sexuel dans la leucémie lymphoïde chronique (LLC). Congrès de la Société Française d'Hématologie, Paris, France, March 2012 (seminar)

**3. Développements instrumentaux et méthodologiques****Prototypes et démonstrateurs**

**2014**

Arock M, Valent P, Saleh R, Wedeh G, Auclair C. Development of new *in vitro* and *in vivo* models of KIT D816V+ aggressive systemic mastocytosis. International patent EP2773749A1, EP2773749B1, US20140298497, WO2013064639 A1: “Human mast cell lines, preparation and uses” Publication date : 2 october 2014.

**Plateformes et observatoires**

Sans objet

**4. Produits et outils informatiques****Logiciels**

Sans objet

**Bases de données / cohortes****2015**

Arock M. Design and maintenance of the Database of French patients with mastocytosis (French Mastocytosis Reference Center, CEREMAST): [https://ssl.voozanoo.net/VOOCEREMAST/scripts/authentify.php?voo\\_2130313390=8vifsi4sk41vqbis7bcq1pou74&msg=](https://ssl.voozanoo.net/VOOCEREMAST/scripts/authentify.php?voo_2130313390=8vifsi4sk41vqbis7bcq1pou74&msg=)

Arock M. Design and maintenance of the Database of European patients with mastocytosis (European Competence Network on Mastocytosis; ECNM): <https://ecnm-registry.oekb-bs.at/pages/examination/followUpExamination/followUpExaminationList.xhtml>

**2014**

Nadal N, Chapiro E. t(9;14)(q33;q32) IGH/LHX2. Atlas Genet Cytogenet Oncol Haematol. 2014;18(6):438-440. <http://AtlasGeneticsOncology.org/Anomalies/t0914q33q32ID1659.html>

**2012**

Delettre C, Yuste VJ, Moubarak R, Bras M, Susin SA. Nucleotidic sequence of 3 new isoforms of Apoptosis Inducing Factor human and mouse (5 entrées). GenBank (N° d'accès DQ016496-DQ016500).

Chapiro E, Nguyen-Khac F. t(11;14)(q24;q32) IGH/miR-125b-1. Atlas Genet Cytogenet Oncol Haematol. 2012; 16(10):746-748. <http://AtlasGeneticsOncology.org/Anomalies/t1114q24q32IGHMIR125B1ID1587.html>

**Corpus**

Sans objet

**Outils présentés dans le cadre de compétitions de solveurs**

Sans objet

**Outils d'aide à la décision****2013**

Davy F. EuroClonality : online help provided by a panel of experts for problematic cases of clonality testing in lymphoproliferative disorders (<http://www.euroclonality.org/online-support-form/>)

**2012**

Arock M, Chemla G, Chemla JP. ADH (Diagnostic Assistance in Hematology) software. Editions Springer-Verlag France, Paris.

**5. Brevets, licences et déclarations d'invention**

*The teams filled 4 patents for the period 2012-2017*

**2016**

Karoyan P, Launay P, Merle-Beral H, Susin SA. New compounds and pharmaceutical use thereof in the treatment of cancer. EP16305541.1

**2014**

Arock M, Valent P, Saleh R, Wedeh G, Auclair C. Human mast cell lines, preparation and uses. EP2773749A1, EP2773749B1, US20140298497, WO2013064639 A1. October 2014.

Karoyan P, Launay P, Merle-Beral H, Susin SA. In vitro method for classifying patient suffering from cancer, comprises determining expression level of phospholipase-C gamma-1 in a sample, comparing expression level with predetermined reference value and providing stage of patient. PCT/EP2014/077335 (WO2015086727-A2). June 2014

**2013**

Karoyan P, Launay P, Merle-Beral H, Susin SA. (2013). Use of soluble peptide comprising specific amino acids sequence or its function-conservative variant in the treatment of cancer e.g. refractory B-chronic lymphocytic leukemia, adrenal cortical cancer, anal cancer, bile duct cancer. PCT/EP2013/061727 (WO2013182650 A1).

**6. Rapports d'expertises techniques, produits des instances de normalisation**

Sans objet

**7. Produits des activités didactiques****Ouvrages****2017**

Nguyen-Khac F : Polycopié DFASM2, UPMC Paris 6

**E-learning, moocs, cours multimedia, etc.**

Nguyen-Khac F : Cas cliniques (Dossiers progressifs) Etudiants en médecine DFASM2 (3 examens/an)

Nguyen-Thac F : Base SIDES : correction de dossiers progressifs, QCM.

**8. Produits destinés au grand public****Émissions radio, TV****2017**

Merle-Béral H. France Culture, Les discussions du soir de René Frydman. January 2017

**2016**

Merle-Béral H. Radio Chalom Nice. La parole aux grands. December 2016

Djavaheri-Mergny M. France 3. Présentation de l'institut Bergonié et vulgarisation du processus autophagie et son rôle dans le cancer ". October 2016

Merle-Béral H. Radio Canada. Les années-lumière. October 2016

Merle-Béral H. RTL. La curiosité est un vilain défaut. October 2016

Merle-Béral H. RTS (Radio Télévision Suisse). CQFD. October 2016

Merle-Béral H France Inter. Carnet de santé dans le 7/9 du week-end. October 2016

Merle-Béral H. Fréquence Protestante. Parcours Scientifique. September 2016

Merle-Béral H. RFI (Radio France Internationale). Autour de la question. September 2016

Merle-Béral H. I-Télé. September 2016

Merle-Béral H. France Culture. La conversation scientifique avec Etienne Klein. January 2016

Merle-Béral H. France 3 TV. Les matins de Paris. November 2016

## 2014

Le Garff-Tavernier M : Chanel 5, France Television-Allo Docteurs, « La leucémie, quand le cancer s'attaque au sang ». April 2014

## Presse écrite

### 2017

Merle-Béral H. Cerveau & Psycho. January 2017

### 2016

Merle-Béral H. Les 20 meilleurs livres de l'année: finaliste dans la catégorie Sciences. December 2016:

Merle-Béral H. EducPros, November 2016

Merle-Béral H. L'amour des livres: September 2016

Merle-Béral H. Lire: November 2016

Merle-Béral H. Actualités pharmaceutiques, November 2016

Djavaheri-Mergny M. L'autophagie ce processus cannibale. Journal du Sud-Ouest. October 2016.

Merle-Béral H. A fond la science (web): du livre à l'expérience. October 2016

Merle-Béral H. Sud-Ouest Dimanche. October 2016

Merle-Béral H. Paris-Match. October 2016

Merle-Béral H. Le Point. October 2016

Merle-Béral H. Le Figaro. October 2016

Merle-Béral H. Le Monde. October 2016

Merle-Béral H. Le quotidien du Médecin. October 2016

Merle-Béral H. La Croix. September 2016

Merle-Béral H. Direct Matin. September 2016

Merle-Béral H. Les Echos. September 2016

## Produits de vulgarisation : articles, interviews, éditions, vidéos, etc.

### Interviews:

#### 2017

Nguyen-Khac F. Correspondances en onco-hématologie: iwCLL meeting, Nex York USA 2017: LLC et cytogénétique

#### 2016

Nguyen-Khac F. Hémato.net: Congrès de la Société française d'Hématologie: actualités en cytogénétique, Paris, March 2016

Nguyen-Khac F. Cancéro.net: American Society of Hematology annual meeting, San Diego USA 2016: actualités génomiques dans la LLC

Arock M. Hémato.net: le direct du congrès de la Société Française d'Hématologie (SFH): interview sur les mastocytoses systémiques, March 2016.

[http://sfh2016.cr.hemato.net/index.php?pageID=toutes\\_les\\_interview\\_video](http://sfh2016.cr.hemato.net/index.php?pageID=toutes_les_interview_video)

Conférences, débats, vidéos**2017**

Merle-Béral H. Conférence EducPros: Recherche: partenariats, recrutement, financements, big data : quelles stratégies adopter ? Débat: Quelle place pour les femmes dans la recherche ? Paris, June 2017

Merle-Béral H. La Fête du Livre. Interviews et signatures. Hyères, May 2017

Merle-Béral H. Café littéraire organisé par le GEM (groupement des écrivains médecins) Paris. March 2017

Merle-Béral H. Dîner/conférence au Sénat invitée par le PWN (Professional women's network). Paris, March 2017

Merle-Béral H. Les rencontres à la librairie Ombres Blanches. Débat conférence et signatures. Toulouse, February 2017.

**2016**

Merle-Béral H. Rencontres littéraires. Les idées mènent le monde: le Progrès. Débat-conférence, interviews et signatures. Pau, November 2016.

Merle-Béral H. Librairie Mollat (Bordeaux). Vidéo. October 2016

**Produits de médiation scientifique**

Sans objet

**Débats science et société**

Sans objet

**9. Autres produits propres à une discipline****Créations artistiques théorisées**

Sans objet

**Mises en scènes**

Sans objet

**Films**

Sans objet

**II. ACTIVITÉS DE RECHERCHE ET INDICES DE RECONNAISSANCE****1. Activités éditoriales**

*Teams members participate as editors in international journals and international associations.*

**Participation à des comités éditoriaux (revues, collections)**Susin SA

- Member of the Editorial Board of the journal "Apoptosis", since 2007
- Member of the Editorial Board of the journal "IUBMB Life", since 2012

Nguyen-Thac F



- Member of American Journal of Blood Research, since 2011
- Member of World Journal of Hematology, since 2012
- Member of Clinics in Oncology, since 2016

#### Arock M

- Member of the Editorial Board of the journal “Annales Pharmaceutiques Françaises”
- Member of the editorial committee “Cytokines and Soluble Mediators in Immunity” (section of Frontiers in Immunology)

#### Djavaheri-Mergny M

- Member of the American Journal of Cancer Research (2011)

## 2. Activités d'évaluation

Members of the team participated in evaluation instances and grant funding organizations in Europe, North and South America, such as NIH and NCI (USA), FNRS (Belgium), CSIC (Spain), AGAUR (Spain), DKFZ-Israel, Leukaemia & Lymphoma Research (UK), ISF and BSF (Israel).

Team members participated during the last years in manuscript assessment for over 75 different journals, including Blood, Leukemia, EMBO J, JCI, JEM, Haematologica, Cancer Res, etc.

The notoriety of the team is also evident at national level, where members hold key positions in panels for grants and fellowships evaluation in the most representative French caritative foundations (Fondation de France, Ligue contre le Cancer, Fondation pour la Recherche Medicale, Cancéropôle GSO, and GEFLUC). The members have also participated in more than 30 PhD and HDR evaluation comitees.

### Responsabilités au sein d'instances d'évaluation

#### Susin SA

- Member of the Scientific Council - Fondation pour la Recherche Medicale (2016-2020)
- Member of the Comité Cancer - Fondation de France (2011-2016)
- HDR comitees: K. Andreau 2012
- PhD comitees: H. Boujrad 2012, M. Samy 2012, E. Fouquerel 2012, M Saison-Ridinger 2013, C. Gallerne 2013, A-C Martinez-Torres 2013, M. Baritaud 2013, L. Saad 2014, L Cabon 2014, A Cosson 2015, J Debernardi 2016

#### Nguyen-Khac F

- Member of the Comité Cancer - Fondation de France (2017-2022)
- Member of the Scientific Council - GEFLUC (Groupement des entreprises françaises dans la lutte contre le cancer) (since 2015)
- Head of the Scientific Council - Force Hémato (since 2016)
- Member of the scientific committee of the GCF-LLC/MW-GOELAMS.
- Cancéropôle Ile-de France: groupe de travail franco-américain en bioinformatique, Seattle 2013
- HDR comitees: R Letestu 2012
- PhD comitees: D Guenat 2015, E Pronier 2013

#### Merle-Béral H

- Founder member of FoRCE Hemato (foundation for the development of clinical research in Hematology)
- Member of SILLC (association for the information and the support of patients with chronic lymphocytic leukemia and Waldenström disease, and GCF-LLC/MW-GOELAMS)
- Member of the Etude ANRS du protocole Lymphome et HCV
- Jury for the “ grands prix de la Chancellerie (prix Kuntz et Forest )”
- Expert member hematologist with the medical committee of INSERM

#### Davi F

- Member of Euroclonality (<http://www.euroclonality.org>), a European network dedicated to standardization and development of molecular clonality analyses of lymphoproliferative disorders

-Co-founder of IgCLL (<http://igcll.org>), a European network specialized in Ig sequences analyses in CLL. The IgCLL group is part of the European Research Initiative in CLL (ERIC) and also provides guidelines and education for Ig sequence analysis

- Member of the scientific committee of the GCF-LLC/MW-GOELAMS

Bauvois B

-PhD committees: C Rouault 2013, A Brisac 2017

Djavaheri-Mergny M

-Member of the Scientific Council - Cancéropôle GSO (since 2013)  
 -Member of the Scientific Council - Club Francophone de l'autophagie (since 2015)  
 -Member of the Scientific Council - Fédération de Recherche Transbiomed (2012-2016)  
 -PhD committees: Jin Liu 2017, F Lecann 2017, J Frentze 2016, R Surya 2016, A Dubois, 2016; A Bettoun 2015, S Jawhari 2015, Y Wang 2014, S Diouani 2013, C Roux 2013, A Belaïd 2013, M Yassine 2013.

**Évaluation d'articles et d'ouvrages scientifiques**

Susin SA. Apoptosis, Biochimie, Blood, British Journal of Cancer, Annals of Hematology, Cancer Letters, Cancer Research, Cell Death & Differentiation, Experimental Hematology, EMBO Journal, FASEB Journal, FEBS Letters, European Journal of Immunology, International Journal of Cancer, IUBMB Life, Journal of Biological Chemistry, Journal of Experimental Medicine, Journal of Molecular Biology, Journal of Neuroscience, Journal of Neurochemistry, Leukemia, Molecular Cancer Therapeutics, Molecular and Cellular Biology, Molecular Biology of the Cell, Neuroscience, Oncogene.

Nguyen-Khac F. Leukemia, Haematologica, Genes Chromosomes Cancer, American Journal of Hematology, Leukemia Research, Leukemia Lymphoma, Tumor Biology, Journal of Visualized Experiments, BMC medicine, Clinical Genetics.

Abstracts for congress: Congrès Assises de Génétique 2013, EHA meeting 2012, Congrès ACLF 2014, 2016.

Davi F. Blood, Leukemia, Haematologica, American Journal of Hematology, Molecular Medicine, Journal of Hematopathology, Leukemia Research, Leukemia and Lymphoma.

Chapiro E. Blood, Leukemia Research

Roos-Weil D. Blood, American Journal of Hematology.

Arock M. Annals of Hematology, Blood, Cellular Immunology, Clinical and Experimental Allergy, Journal of Clinical Investigation, The Journal of Allergy and Clinical Immunology, The Journal of Immunology.

Bauvois B. Biochimie, J Mol Med, Cell Death & Disease, Oncotarget, PlosOne, J Leuk Biol, Cancers, Oncogene, Haematologica, Oncoimmunology, International Journal of Immunopathology, Journal of Pharmacy and Pharmacology, European Journal of Inflammation.

Djavaheri-Mergny M. Autophagy, Biochimie, Carcinogenesis, Cancer Letters, CDDiscovery, FEBS Letters, Oncogene, Oncotarget.

Le Garff-Tavernier M. Neuro-Oncology

**Évaluation de laboratoires (type Hceres)**

Susin SA. Member of the Scientific Advisory Board (SAB) CSIC (Spain), AGAUR (Spain).

Arock M. Chairman of the Scientific Advisory Board (SAB), Ludwig Boltzmann Cluster for Oncology (LBC-ONC), Medical University of Vienna (MUV) (AUSTRIA). 2012

Davi F. Member of the SAB for evaluation of the Research Team EA3963 (Lymphocyte differentiation and lymphoid disorders). Jean-Christophe Bories, Institut Universitaire d'Hématologie, Université Denis Diderot Paris 7. 2012

**Évaluation de projets de recherche****2017**

Susin SA. ERC-Starting Grants, FRM, ARC, Fondation de France, FNRS

Djavaheri-Mergny M. Mitac

**2016**

Susin SA. ANR, FRM, Fondation de France, FNRS

Arock M. Call for projects Biobanks INSERM

Bauvois B. Ligue contre le Cancer/Comité du Loiret

Djavaheri-Mergny M. Cancéropôle PACA, Mitac

## 2015

Susin SA. ANR, ARC, FNRS, AGAUR, AMSUD, Fondation de France, Leukaemia & Lymphoma Research

Nguyen-Thac F. Ligue nationale contre le cancer, Ligue Contre le Cancer Inter Région Rhône-Alpes-Auvergne, Institut Universitaire d'Ingénierie en Santé (IUIS) de Sorbonne Universités

Davi F. Ligue Contre le Cancer - InterRégion Rhône-Alpes-Auvergne-Drome-Saonne et Loire

Djavaheri-Mergny M.. Idex Paris Sorbonne, Swiss Cancer League

## 2014

Susin SA. FNRS, FRM, AGAUR, AMSUD, Pasteur Institute, Labex Lermite, Fondation de France, Telethon Italie

Nguyen-Thac F. Ligue nationale contre le cancer, Leukemia Lymphoma Research, EHA research fellowship application

Davi F. Conseil Régional Limousin - Université de Limoges:Projet LyRIC (Lymphoma Radio Immunotherapy Connection)

Bauvois B. Life Science EcoS-Sud, Israël Science Foundation, KU Leuven (University of Leuven, Belgium)

Djavaheri-Mergny M. Ligue nationale contre le cancer, Biotechnology and Biological Sciences Research Council

## 2013

Susin SA. Année recherché IDF, FNRS, ECOS-SUD, Fondation de France, Telethon Italie

Bauvois B. ANR-Emergence

Djavaheri-Mergny M. Swiss Cancer League, cancéropôle GSO, Transbiomed Bordeaux

## 2012

Susin SA. FNRS, US-Israel, ANR Emergence, ECOS-SUD, Fondation de France, ISF-Israel Cooperation Program

Nguyen-Thac F. DKFZ-Israel Cooperation Program

Bauvois B. Life Science EcoS-Sud

### 3. Activités d'expertise scientifique

*Team members consult for 4 different companies.*

#### Activités de consultant

##### Since 2015

Arock M. Consultant for the Pharmaceutical Company **Deciphera Pharmaceuticals, LLC**, Waltham, MA 02451, USA.

##### Since 2016

Arock M. Consultant for the Industrial Company **Philips Electronics Nederland bv**, 5600 JT Eindhoven, The Netherlands.

Le Garff-Tavernier M. Advisory Board of **Alexion Pharmaceuticals France**.

**2015-2016**

Davi F. Consultant for Gilead Sciences.

**Participation à des instances d'expertises (type Anses) ou de normalisation**

Sans objet

**Expertise juridique**

Sans objet

**4. Organisation de colloques / congress**

*Team members contributed to the organization of 6 different international and national conferences.*

**2017**

Arock M. Organization of the 15th International meeting of the European competence network on mastocytosis (ECNM), <http://ecnm2017.fr/>Imagine Institute, Paris (FRANCE): 12-14 October 2017.

**2016**

Djavaheri-Mergny M. Co-organisateur des 6<sup>èmes</sup> journées du Club Francophone d'autophagie. Bordeaux, 12-14 Octobre, 2016.

**2015**

Davi F. International Splenic Lymphoma Study Group Meeting (co-organized with Pr Catherine Thieblemont), Hôpital Saint-Louis, Paris, 9-10 October, 2015

Le Garff-Tavernier M, Letestu R, Wagner-Ballon O, Chatelain B. Organization of a thematic day on PNH (Paroxysmal Nocturnal Hemoglobinuria) disease, in collaboration with AFC (Association Française de Cytométrie) and Alexion Pharmaceuticals France, Antibes Juan-Les-Pins, France, 17<sup>th</sup> November 2015

**2014**

Susin SA. Co-organized an international meeting "Cell Death & The Immune System", Zaragoza (Spain)

**2013**

Davi F. 3rd workshop Normal and neoplastic B cells, Ile d'Oléron, 19-22 September

**5. Post-doctorants et chercheurs accueillis**

*Since 2012, the members of the new team members hosted 7 post docs (4 foreign researchers).*

Susin SA. Laure Delavallée (2012-2015), funds INCa and ANR, 4 manuscripts; Laura Vela (2013-2015), funds INCa, 2 manuscripts; Claire Quiney (2011-2014), funds FRM and ANR, 2 manuscripts; and Patricia Galan-Malo (2011-13), funds ANR, 4 manuscripts.

Arock M. Ghaith Wedeh (2016-2017), funds Astellas Pharmaceuticals, Santa Monica, CA 90403, USA, 1 manuscript.

Djavaheri-Mergny M. Kelly Airiau (2014-2016), funds Conseil Régional d'Aquitaine et SIRIC Brio; Faten Merhi (2012-2014), funds Conseil Régional d'Aquitaine, 1 manuscript.

Additionally, the members of our team have trained and prepared **11 PhD students**. Four other PhD students will defend their thesis in 2018. Note that 6 PhD students are from foreign countries, which highlight the attractiveness of our team. During this period, we also trained **13 Master students** and **two ERASMUS** students.

## 6. Interactions avec les acteurs socio-économiques

### Contrats de R&D avec des industriels

*The members of the team conduct projects funded by Merck Sharp & Dohme, Agensys, Deciphera, Blueprint Medicines, Gefluc, Medice Paris region, LFB, BD Biosciences, and Roche.*

#### 2016-2017

Nguyen-Khac F. Roche France. 40 k€

Davi F. Merck Sharp & Dohme. Integrated Discovery of new Immuno-Molecular Actionable Biomarkers for Tumors with immune-suppressed environment (IDeATlon). 1.5 M€ (to be redistributed in the consortium)

Arock M. Agensys Inc. In vitro and in vivo demonstration of the interest of the mast cell antigen CD203c as a therapeutic target during systemic mastocytosis. 75 K€.

#### 2015-2016

Arock M. Deciphera. In vivo study of the effects of a novel inhibitor of KIT D816V on the proliferation of human neoplastic mast cells grafted to immunodeficient mice. 90 K€.

Arock M. Blueprint Medicines. 15 K€. In vitro study of the effects of KIT D816V inhibitors on the proliferation of human neoplastic mast cells.

#### 2014

Bauvois B. Gefluc. 7,5 K€). Ciblage de l'antigène CD13 tumoral par un biopeptide pro-apoptotique comme nouvelle approche thérapeutique dans les leucémies aiguës myéloblastiques.

#### 2013

Susin SA. Pole de Competitivité Medice Paris Region. 160 k€. Hexocan.

#### 2012

Merle-Beral H. LFB. 320 k€. Development of novel anti-CD20 antibodies. BD Biosciences. 60 k€. sCD23 as a marker of chronic lymphocytic leukemia. Roche. 320 k€. Chronic lymphocytic leukemia tests.

Djavaheri-Mergny M. Roche. 35 k€. Autophagy: a new therapeutic target in diffuse large B-cell lymphoma.

Bauvois B. Gefluc. 10 K€. Leucémies aiguës myéloblastiques: importance de l'aminopeptidase-N/CD13 dans la transformation leucémique. Intérêt du blocage de CD13 dans l'induction d'apoptose.

### Bourses Cifre

Sans objet

### Créations de laboratoires communs avec une / des entreprise(s)

Sans objet

### Création de réseaux ou d'unités mixtes technologiques

#### 2017

Davi F. Collaboration avec Pr JF. Emile (EA4340, Versailles University, Paris-Saclay university, Boulogne, France) et Pr J. Haroche (AP-HP, University Hospital La Pitie-Salpetriere, Department of internal medicine, Centre de référence des histiocytoses, Paris, France) sur le lien entre histiocytoses et hémopathies myéloïdes. Publication : Durham BH, Roos-Weil D, Baillou C et al. Blood 2017.

#### Since 2016

Le Garff-Tavernier M. Wagner-Ballon Oriane, Principal Investigators of the French PNH National Observatory

## Créations d'entreprises, de start-up

Sans objet

### 7. Contrats de recherche financés par des institutions publiques ou caritatives

The team obtained international and national funds, including French-Singapore collaboration, ANR, ANRS, INCa, and different French regions. We also received funding from cancer caritative foundations, including FRM, ARC, Ligue Contre le Cancer, Association Laurette Fugain, and Fondation de France. Altogether, this makes a total budget for the 5 years of >2.5 million euros.

#### Contrats européens (ERC, H2020, etc.) et internationaux (NSF, JSPS, NIH, Banque mondiale, FAO , etc.)

Arock M. MERLION Program (financed by the French embassy in Singapore). Joint collaborative program between Singapore (NUS Duke University, Soman Abraham) and CNRS. A Critical Role for Mast Cell Responses in Pathophysiology of the Dengue Infections. Principal Investigator. 60 K€. 2013

#### Contrats nationaux (ANR, PHRC, FUI, INCA, etc.)

Susin SA. INCa PL-BIO. PLC $\gamma$ 1 and calcium signaling in caspase-independent cell death: new therapeutic targets in chronic lymphocytic leukemia. Principal Investigator. 495 k€. 2013-2016

Susin SA. Inserm Transfert- Grand COPOC CD47 peptide-triggering: a new therapeutic strategy against chronic lymphocytic leukemia. Principal Investigator. 250 k€. 2014-2016

Susin SA. ANR. Cell death induction by CD47 peptide-triggering: a new therapeutic strategy in the management of chronic lymphocytic leukemia. Principal Investigator. 250 k€. 2013-2015

Susin SA. ANR. AIF-mediated caspase-independent cell death: molecular mechanisms. Principal Investigator. 248 k€. 2010-2013

Nguyen-Khac F. TOURS PHRC LLC SA 2007. Principal Investigator. 25K€. 2017

Nguyen-Khac F. ITMO cancer: Programme leucémie polylmphocytaire. Co-IP. 37.5K€. 2014

Davi F. ANRS. Molecular characterization of HCV-associated lymphomas. Co-PI. 80 K€. 2016-2018

Davi F. Institut d'Ingénierie en Santé-Sorbonne Universités. Clonality of lymphoid proliferations: Bioinformatic tools for high throughput analyses. Co-PI. 10 K€. 2015

Djavaheri-Mergny M. Siric Brio - INCa-DGOS-Inserm 6046. Etude de l'impact du métabolisme mitochondrial des cellules leucémiques dans leur résistance au traitement. Co-IP. 14.2 k€. 2016

Djavaheri-Mergny M. Siric Brio - INCa-DGOS-Inserm 6046. Etude in vivo des ligands G4. Co-PI. 11.4 k€. 2015.

Djavaheri-Mergny M. Cancéropôle Sud-Ouest. Caractérisation d'une nouvelle voie oncogénique dans le cancer colorectal: rôle du cross-talk MAP3K-N-kB. Co-IP. 20 k€. 2012

#### Contrats avec les collectivités territoriales

Djavaheri-Mergny M. FR Transbiomed Bordeaux. Role of autophagy in keratinocytes responses to UVB and UVB-induced cancer initiation and progression. Co-IP. 20 k€. 2015

Djavaheri-Mergny M. Région Aquitaine et Institut Bergonié. Etude de la régulation de Beclin 1 et de sa fonction dans les lymphomes diffus à grandes cellules B. Co-IP. 120 k€. 2012-2014

Djavaheri-Mergny M. Conseil Régional d'Aquitaine and INCa-DGOS-Inserm 6046. Identification des mécanismes moléculaires qui contrôlent l'autophagie dans les hémopathies malignes. Co-IP. 120 k€. 2014

Djavaheri-Mergny M. FR Transbiomed Bordeaux. L'autophagie régule-t-elle le métabolisme énergétique des cellules leucémiques au cours de leur engagement vers la différenciation granulocytaire? Equipe associée, Rodrigue Rossignol Laboratoire MRGM, Université de Bordeaux. Co-IP. 20 k€. 2014.

## Contrats financés dans le cadre du PIA

Sans objet

## Contrats financés par des associations caritatives et des fondations (ARC, FMR, FRM, etc.)

Susin SA. Fondation pour la Recherche Médicale (FRM): " Cell Death and Drug Resistance in Lymphoproliferative Disorders ". Principal Investigator. 100 k€. 2016-2018.

Susin SA. Association pour la Recherche sur le Cancer (ARC): " Mort cellulaire programmée induite par des peptides agonistes du récepteur CD47: une nouvelle stratégie pour le traitement de la leucémie lymphoïde chronique ". Principal Investigator. 50 k€. 2016-2017.

Susin SA. Ligue contre le Cancer-Comité de Paris: " CD47 peptide-triggering: a new therapeutic strategy against chronic lymphocytic leukemia ". Principal Investigator. 40 k€. 2016-2017.

Susin SA. Association Laurette Fugain: " Mort cellulaire programmée induite par des peptides agonistes du récepteur CD47: une nouvelle stratégie pour le traitement de la leucémie lymphoïde chronique ". Principal Investigator. 50 k€. 2015-2016.

Susin SA. Association Laurette Fugain: " Calcium et mort cellulaire programmée indépendante des caspases: vers le design de nouvelles approches thérapeutiques dans la leucémie lymphoïde chronique". Principal Investigator. 50 k€. 2011-2013.

Susin SA. Ligue contre le Cancer-Comité de Paris: " Mort cellulaire indépendante des caspases médiée par AIF: Analyse de sa régulation et de son importance physiologique ". Principal Investigator. 40 k€. 2012-2013.

Susin SA. Fondation de France-Comité Cancer: " Résistance à l'apoptose dans la leucémie lymphoïde chronique B: Rôle de AAC-11". Principal Investigator. 50 k€. 2012-2013.

Nguyen-Khac F. Association Laurette Fugain: " Rôle de XPO1 dans la leucémie lymphoïde chronique (LLC)". Principal Investigator. 50 k€. 2015-2016.

Nguyen-Khac F. Association pour la Recherche sur le Cancer (ARC): " Caractérisation des gènes impliqués dans les gains du bras court du chromosome 2 dans la leucémie lymphoïde chronique ". Principal Investigator. 50 k€. 2012-2013.

Nguyen-Khac F. Intergroupe FILO/LLC: " Biologie des LLC". Principal Investigator. 40 K€. 2015.

Nguyen-Khac F. Intergroupe FILO/LLC: "Séquençage à haut débit, protocole LLC SA 2007". Principal Investigator. 50 K€. 2015.

Nguyen-Khac F. Intergroupe FILO/LLC: "Séquençage à haut débit, protocole LLC FMP2007". Principal Investigator. 10K€. 2014.

Djavaheri-Mergny M. Ligue contre le cancer de la région Aquitaine: "Evaluation du rôle de l'autophagie dans l'effet anti-tumoral de ligands de G-quadruplexes". Principal Investigator. 13 k€. 2013

## 8. Indices de reconnaissance

*Prestigious awards were received, including for investment in medical research (Susin, Nguyen-Khac). The members of the two teams received 106 invitations for presentations at conferences and seminars at international and national level. Researchers of the teams have responsibilities in 15 different scientific organizations.*

### Prix

Susin SA. Academy of Medicine (Spain) 2014

Armand M, Costopoulos M, Charlotte F, Maloum K, Alentorn A, Choquet S, Davi F, Leblond V, Le Garff-Tavernier M. Lymphoma Prize - 2<sup>nd</sup> prize - Colocataires mais non apparentées ! À propos de 2 hémopathies rares. Published in Correspondances en Onco-Hématologie / N° 2 / avril 2017.

Nabila Belhouachi and Frédéric Davi. Prix de la Société Française d'Hématologie 2012.

### Distinctions

Susin SA. Prime d'Excellence Scientifique (CNRS)

Nguyen-Khac F. Prime d'encadrement doctoral et de recherche (PEDR), 2008-12; Prime d'investissement recherche (PIR), UPMC 2013-17

### Responsabilités dans des sociétés savantes

Susin SA

- Member of the *Federation of European Biochemical Societies*, since 2011
- Member of the *Americal Society for Microbiology*, since 2011

Nguyen-Khac F

- Member of the American Society of Hematology (ASH)
- Member of the European Haematology Association (EHA)
- Head of the Groupe Francophone de Cytogenetique hematologique (GFCH)
- Board member of the Association des cytogeneticiens de langue francaise (ACLF)
- Member of the French Society of Hematology (SFH)

Merle-Béral H.

- Member of the American Society of Hematology (ASH)
- Member of the European Haematology Association (EHA)
- Member of the French Group of Cellular Hematology (GFHC)
- Member of the French Association of Cytometry (AFC)
- Member of the French Society of Hematology (SFH)
- Member of the French Society of Immunology (SFI)

Davi F

- Member of the European Society of Haematology
- Member of the French Society of Hematology
- Member of the French Society of Immunology
- Board member of EuroClonality
- Board member the AP-HP Molecular Cancer Genetics Platform

Arock M:

- Member of the French National Academy of Pharmacy and Chairman of the 3rd Section (Medical Biology Section)
- Member of the Board of Directors of the French Society of Clinical Biology
- Founding member and Vice-Chairman of the French Group for the Study of Human Mastocytosis and the French Association for mast cell and Mastocytosis Research Initiatives (AFIRMM)
- Member of the Scientific Committee of the French Reference Center for Mastocytosis (CEREMAST)
- Founding member and Chairman of the European Competence Network on Mastocytosis (ECNM) (ECNM; <http://www.univie.ac.at/ecnm/>). European network of researchers and clinicians working on mastocytosis.

Chapiro E

- Member of the French Group of Hematological Cytogenetics (GFCH)
- Member of the French Society of Hematology (SFH)

Djavaheri-Mergny M

- Member of ECDO (European Cell Death Organization) *since 2009*
- Member of CFAT (Club Francophone de l'autophagie) *since 2009*
- Member of SBCF (Société de biologie cellulaire de France) *since 2009*

Le Garff-Tavernier M

- Member of the French Association of Cytometry (AFC)
- Member of the French Society of Hematology (SFH)

### Invitations à des colloques / congrès à l'étranger, séjours dans des laboratoires étrangers

The PIs of the team were present or invited to speak in 45 French congresses (SA Susin 8, F Nguyen-Khac 12; F Davi 4; H Merle-Béral 15; M. Arock 3; M. Le Garff-Tavernier 2; M. Djavaheri-Mergny 1), 53 international symposiums (SA Susin 7, H Merle-Béral 15; F Nguyen-Khac 12; F Davi 4; M. Arock 13; M. Djavaheri-Mergny 2).



The international invitations included congresses in Israel, USA, Denmark, Austria, Morocco, Italy, England, Sweden, Ireland, Germany, Iran, and Czech Republic.